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 1 INTRODUCTION
 1.1 Alzheimer's disease (AD) 
Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by a progressive cognit-
ive decline. According to recent studies, more than 35 million people worldwide (Wimo & Prince 
2010) or rather more than 800.000 people in Germany suffer from AD (Bickel 2010). Because of  
an increased life  expectancy  in  western industrial  countries  the number of  dementia  cases  is 
estimated to double every 20 years  (Wimo & Prince 2010). AD is the most common form of  
dementia diagnosed in mid-to-late life, affecting 7–10 % of  all individuals over 65 years of  age 
and approximately 40 % of  all persons over 80 years of  age  (Sisodia 1999; Prince & Jackson 
2009).  In  the  beginning  of  the  disease,  affected people  show an impairment  of  short  term 
memory, language and cognitive functions. Further they have paranoia, delusions and show a loss 
of  social appropriateness. Later all these hallmarks become intensified and additional problems 
with motor and sensory functions become manifested. AD is a terminal disease, but the most fre-
quent cause of  death are pneumonia and myocardial infarction and not the disease itself  (Forstl 
& Kurz 1999). The symptoms are attributed to alterations or loss of  neurons in several brain 
areas or neural systems including the cortex, hippocampus, amygdala, anterior thalamus, basal 
forebrain and several brainstem regions (Sisodia 1999; Wenk 2003; Jalbert et al., 2008).
More  than  100  years  after  the  first  description  of  AD  by  the  german  psychiatrist  Alois 
Alzheimer, this severe form of  dementia is still not fully understood. However, there is evidence 
that besides age also high cholesterol levels and diabetes are risk factors for AD (Tan et al., 2003; 
Akomolafe et al., 2006). AD cases can be classified into the so-called early onset forms and the 
late onset forms. Only about 5 % of  all AD cases account for early-onset AD (EOAD) in which 
genetic mutations either in the amyloid precursor protein (APP) or in presenilins 1 and 2 (PS1, 
PS2)  are  associated with  an  age-of-onset  below 65 years,  with  some  really  severe  mutations 
already between 20-40 (Selkoe 2001).
In contrast, cases of  late-onset AD (LOAD) which are also called sporadic AD are not linked to 
mutations in APP or PS, but genetic determinations like ApoE4 are known to increase the risk 
for developing AD.
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 1.1.1 Neuropathological hallmarks of  AD
Both the sporadic and the familiar forms exhibit the same histopathological characteristics: neur-
ofibrillary tangles and β-amyloid plaques, appearing mostly in the neocortex, hippocampus and in 
the limbic system (Braak & Braak 1996). There are several hypotheses how these hallmarks can 
account for the very complex pathology of  AD and how they could be linked.
 1.1.1.1 Neurofibrillary tangles
Neurofibrillary tangles (see fig. 1) are intraneuronal accumulations of  hyperphosphorylated forms 
of  the tau protein. Under physiological conditions tau is associated with microtubules in axonal 
compartments, forming and stabilizing their structure  (Grundke-Iqbal et al., 1986a; Goedert et 
al., 1988; Friedhoff  et al., 2000). Aside this, tau might have additional functions due to its interac-
tion with the plasma membrane (Brandt et al., 1995; Maas et al., 2000) and the actin cytoskeleton 
(Fulga et al., 2007). Furthermore, a recent paper also highlights a localization and function of  tau 
in dendritic compartments without association to microtubules  (Ittner et al., 2010). The associ-
ation of  tau with microtubules is regulated by phosphorylation  (Drewes et al.,  1995). Several 
kinases including the glycogen synthase kinase 3β (GSK3β) also known as tau kinase 1, the cyclin 
dependent kinase 5 (Cdk5) and the mitogen activated proteinkinase (MAPK) are known to phos-
phorylate tau (Ishiguro et al., 1993; Chung 2009). Under conditions present in AD, tau becomes 
hyperphosphorylated.  The hyperphosphorylated tau loses its binding capacity to the microtu-
bules, thereby destabilizing their structure. Additionally, the hyperphosphorylation enables tau to 
aggregate into so-called paired helical filaments (PHFs) (Alonso et al., 2001). Continuous aggreg-
ation of  PHFs finally forms the neurofibrillary tangles in the soma of  neurons. The combination 
of  the  loss  of  function,  compromising  axonal  transport  through  changes  of  microtubules 
dynamics and the toxic gain of  function forming intracellular protein aggregates results finally in 
cell death of  the affected neurons  (Grundke-Iqbal et al., 1986b; Ishiguro et al., 1993; Li et al., 
2006;  Li  & Paudel  2006;  Ballatore  et  al.,  2007).  Thus,  the intracellular neurofibrillary  tangles 
become detectable in the extracellular environment (Bondareff  et al., 1994).
There is strong evidence that the activity of  protein phosphatase 2A, responsible for the dephos-
phorylation of  tau, is reduced in the brain of  AD patients (Gong et al., 1994; Tian & Wang 2002; 
Chung 2009). However, to date it is not clear whether the hyperphosphorylation of  tau is con-
nected with decreased dephosphorylation, hyperactivity of  the tau related kinases or both (Man-
delkow & Mandelkow 1998).
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In the tau hypothesis  neuronal loss as a  consequence of  the accumulation of  neurofibrillary 
tangles was described as the initial events in the development of  AD. However, there are some 
findings that challenge this. The presence of  hyperphosphorylated tau and tangles is not limited 
to AD (Joachim & Selkoe 1992; Morris et al., 2001). Other neurodegenerative diseases character-
ized by the aggregation of  tau are classified as tauopathies. Important members of  this group are 
the frontotemporal dementia  (Dickson 2009). Moreover, there is no way known in which tau 
could cause amyloid plaques. However, it was shown that tau is mediating Aβ induced cognitive 
impairments and excitotoxicity. The reduction of  endogenous tau in APP transgenic mice pre-
vents behavioral  deficits without affecting Aβ levels by blocking Aβ- and excitotoxin-induced 
neuronal dysfunction  (Roberson et al., 2007). Although the exact mechanism for the rescue is 
unclear, it might be linked to the prevention of  Aβ-induced axonal transport defects  (Vossel et 
al., 2010). While incubation of  primary hippocampal neurons with oligomeric Aβ rapidly inhib-
ited axonal  transport  of  mitochondria  and the  neutrotrophin receptor  TrkA,  these  transport 
defects were rescued in primary neurons of  tau -/- and tau +/- mice (Vossel et al., 2010). Another 
recent study suggests a link by which tau could facilitate Aβ toxicity to synapses. Dendritic local-
ized tau supports the recruitment of  the Src-family kinase Fyn to NMDA (N-methyl-D-aspartic 
acid) receptors on postsynaptic membranes. The resulting phosphorylation of  NMDA receptors 
by Fyn renders them more susceptible to Aβ (Ittner et al., 2010).
Figure 1: Neuropathological hallmarks of  AD.
Representative photographs of  amyloid plaques (left picture) and neurofibrillary tangles (right picture) in an 
AD brain. Scale bar: 62.5 µM. Adopted from “Alzheimer’s disease: Aβ, tau and synaptic dysfunction.” (LaFerla 
& Oddo 2005).
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 1.1.1.2 β-amyloid plaques
In contrast to neurofibrillary tangles, amyloid plaques (fig.  1) are extracellular deposits that are 
also detectable in the basement membranes of  cerebral vessels. One main component of  β-
amyloid plaques is the small hydrophobic β-amyloid peptide (Aβ) which is  derived from the 
amyloid precursor protein (APP), as explained in 1.1.3. Plaques can be microscopically subclassi-
fied into neuritic, also called senile plaques, and diffuse plaques. Neuritic plaques are spherical 
multicellular lesions, consisting of  Aβ fibrils intermixed with non fibrillar variants of  the peptide 
as well as degenerated axons and neurites (Braak & Braak 1996). These compact structures also 
contain a variable number of  activated microglia within and near the fibrillar core. Furthermore, 
the plaques are often surrounded by reactive astrocytes (Mattiace et al., 1990; Pike et al., 1994; 
Jefferies et al., 1996; Stalder et al., 1999).
Diffuse plaques appear mainly in the cerebellum (Yamaguchi et al., 1989). They are mainly com-
posed of  non-fibrillar Aβ (Tagliavini et al., 1988; Yamaguchi et al., 1988), thereby representing 
most likely initial stages of  the plaque pathology in AD (Tagliavini et al., 1988; Giaccone et al., 
1989). In contrast to neuritic plaques which are only found in brains of  AD patients, diffuse 
plaques are also present in brains of  healthy older people  (Hardy & Selkoe 2002). Although 
plaques are strong characteristics of  AD their density and distribution pattern turned out to be 
of  limited significance for differentiation of  neuropathological stages (Braak & Braak 1991).
According to the amyloid-cascade hypothesis, Aβ is the triggering factor of  a severe pathological 
cascade. The accumulation of  Aβ leads to neuronal dysfunction, followed by inflammatory pro-
cesses. The resulting progressive synaptic and neuritic injury entails impaired neuronal homeo-
stasis, thereby altering the activity of  several kinases and phosphatases leading to hyperphos-
phorylation of  tau and favoring the generation of  neurofibrillary tangles. Aβ plaques and neur-
ofibrillary tangles together cause widespread neuronal deficits which end up in dementia (Hardy 
& Selkoe 2002). There are a lot of  in vitro  findings supporting this Aβ cascade hypothesis: the 
impairment of  synaptic activity in hippocampal slice cultures through treatment with naturally 
secreted Aβ oligomers  (Lambert  et al.,  1998;  Walsh et al.,  2002) and Aβ oligomeric species 
extracted from human brains (Shankar et al., 2008) as well as the loss of  memory and cognitive 
functions of  mice and rats injected with natural Aβ oligomers (Cleary et al., 2005; Lesne et al., 
2006; Shankar et al., 2008). There are also some  in vitro evidences that Aβ can modulate the 
activity of  tau phosphorylating kinases (Hooper et al., 2008; Magdesian et al., 2008; De Felice et 
al., 2009; Lee et al., 2009). However, these findings could not be confirmed in animal models. 
No APP single transgenic or APP/PS1 double transgenic animal model which develop plaque 
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pathology is known to exhibit neurofibrillary tangles (Wong et al., 2002). Only triple transgenic 
models,  harboring  PS1M146V,  APPswe and  tauP301L transgenes  progressively  develop  amyloid 
plaques,  neurofibrillary  tangles  and  synaptic  dysfunctions  (Oddo et  al.,  2003a;  Oddo et  al., 
2003b). Also the neuronal loss strongly differs in all AD mouse models (Duyckaerts et al., 2008). 
Moreover, pharmacological reduction of  Aβ load, like immunization fail to delay AD progres-
sion (Small & Duff  2008).
Keeping all pros and cons of  both hypothesis in mind, Small & Duff  proposed a dual pathway 
model in which overriding factors like ApoE4 and GSK3β act in parallel on Aβ- and tau patho-
logy, triggering amyloid plaques as well as neurofibrillary tangles and finally result in synaptic and 
cell loss (Small & Duff  2008). Such a dual pathway model would further explain the importance 
of  ApoE4 as the major genetic risk factor for sporadic AD.
 1.1.2 Genetic factors involved in AD 
 1.1.2.1 Late onset or sporadic AD
Most of  all AD cases belong to the so-called sporadic form of  the disease. Little is known about 
genetic factors underlying this type of  AD pathogenesis. Only the ApoE gene was confirmed as 
risk factor for sporadic AD. The  ApoE gene exists as three polymorphic alleles ε2, ε3 and ε4. 
Individuals bearing one ε4 allele of  the ApoE gene were found to develop AD after the age of  65 
with a three to four times higher risk compared to individuals carrying no ε4 allele (Corder et al., 
1993; Strittmatter et al., 1993; Bertram & Tanzi 2008). In contrast, the ε2 allele was found to be 
protective against sporadic AD (Corder et al., 1993).
ApoE is a 34 kDa protein which appears, corresponding to three alleles, in three different iso-
forms ApoE2, ApoE3 and ApoE4. These isoforms differ only in one or two amino acids (Mah-
ley 1988). ApoE4 is the major lipoprotein in the CNS. In the brain it is predominantly produced 
by astrocytes and to some extent also by microglia (Pitas et al., 1987; Uchihara et al., 1995). The 
uptake into neurons is mediated by a group of  receptors known as the LDL receptors (Herz & 
Bock 2002; Herz & Chen 2006).
The mechanisms underlying the increased risk of  ApoE4 are poorly understood. However, it is 
suggested  that  ApoE4  could  promote  the  Aβ  aggregation  or  could  be  responsible  for  an 
impaired Aβ clearance via receptor mediated endocytosis (Bu 2009; Kim et al., 2009). Indeed, a 
decreased binding capacity of  ApoE4 to Aβ was found compared to ApoE3 (LaDu et al., 1994). 
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Besides ApoE, recent genome wide association studies identified variants of  CLU and PICALM 
to be associated with AD risk (Harold et al., 2009; Corneveaux et al., 2010; Kamboh et al., 2010). 
Nevertheless, all of  them have much lower significance compared to ApoE.
 1.1.2.2 Early onset or familiar AD
About 5 % of  all AD cases are linked to mutations in AD relevant genes. Since these forms 
appear before the age of  65, they are often referred as EOAD (Selkoe 2001). All known muta-
tions linked with EOAD are located in the genes coding for APP or presenilin 1 and 2 and are 
mainly associated with increased Aβ42/Aβ40 ratio and/or alteration of  the Aβ aggregation (Goate 
et al., 1991; Citron et al., 1992; Cai et al., 1993; Borchelt et al., 1996). All mutations in APP are 
located within or nearby the Aβ domain (Wolfe 2007). A well analyzed mutation, which belongs 
to this group is the swedish double mutation. This mutation was initially found in a swedish fam-
ily with EOAD (Mullan et al., 1992). The mutations K595N/M596L in APP increases the affinity 
of  BACE-1 to its substrate APP (Citron et al., 1992; Cai et al., 1993; Vassar et al., 1999). Thus, 
APP bearing this mutation is cleaved earlier and more efficiently in the secretory pathway by 
BACE-1 than APP WT (Haass et al., 1995; Thinakaran et al., 1996). Other mutations in APP near 
the γ-secretase cleavage site lead to increased production of  the more aggregation-prone Aβ42 rel-
ative to Aβ40. Mutations in the Aβ region itself  alter the biophysical properties of  the peptide, 
thereby changing its aggregation and degradation behavior (Wolfe 2007).
So far, more than 160 mutations were identified in the genes encoding PS1 and 2. Most of  them 
are simple missense mutations resulting in the exchange of  one amino acid in PS1, but there are 
also more complex ones, for example small deletions or insertions. The most severe mutation is a 
splice mutation leading to the deletion of  exon 9 (∆exon9) (De Strooper 2007). Such AD causing 
mutations in PS1 lead both to increased Aβ42/Aβ40 ratios (Goate et al., 1991; Citron et al., 1992; 
Cai et al., 1993; Borchelt et al., 1996) and partial loss of  γ-secretase function (Song et al., 1999; 
Bentahir et al., 2006; Tamboli et al., 2008). To explain this apparent paradox at least two different 
cleavage sites of  γ-secretase in APP were assumed. Cleavage at the so-called ε-site produces the 
C-terminus of  Aβ and releases the AICD. Afterwards the cleavage at the γ-site releases Aβ. This 
cleavage site can vary in its position, leading to the various Aβ-species (Aβ40 and Aβ42). Longer 
forms of  Aβ (e.g. Aβ42) are thought to be retained in the active site of  the γ-secretase because of  
their larger hydrophobic tm-domain. Shorter variants (e.g. Aβ40) in contrast are more likely to be 
released. A less active γ-secretase would thereby allow more time for the release of  the longer, 
more hydrophobic Aβ42 (Qi-Takahara et al., 2005; Wolfe 2007).
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 1.1.3 Characteristics of  the β-amyloid precursor protein (APP)
As mentioned above, Aβ originates from a sequential processing of  APP, a large type I trans-
membrane protein, expressed in several human tissues. APP and its homologues APLP-1 and 
APLP-2  (amyloid  precursor  like  protein-1  and -2)  form a  small  family  of  proteins  of  100-
140 kDa in size, which are ubiquitously expressed throughout mammalians as well as Caenorhab-
ditis elegans and Drosophila melanogaster (Goldgaber et al., 1987; Rosen et al., 1989; Luo et al., 1990; 
Daigle & Li 1993; Zheng & Koo 2006). Additional heterogeneity is caused on the one hand by 
alternative splicing (Weidemann et al., 1989; Oltersdorf  et al., 1990; Hung & Selkoe 1994), produ-
cing several isoforms of  which APP 695, 751 and 770 are the most abundant in the brain (Wer-
tkin et al., 1993). On the other hand a couple of  posttranslational modifications as O- and N-
glycosylation  (Tomita et al., 1998), sulfation as well as phosphorylation  (Hung & Selkoe 1994; 
Walter et al., 1997) raises the heterogeneity of  this group of  proteins. APP can be divided in 
three main parts (see fig. 2), a 47 aa long C-terminal cytoplasmic domain, a 24 aa long transmem-
brane domain (tm-domain) and a N-terminal extracellular domain, varying in size between the 
different isoforms.
There are several physiological functions discussed for APP, including modulation of  cell-cell 
interaction,  cell  adhesion,  signal  transduction  and  neurite  outgrowth  (Milward  et  al.,  1992; 
Nishimoto et al., 1993; Koo 2002). Cell-cell contacts and cell adhesion could be mediated by the 
E1 domain of  the extracellular part by which APP is able to form homodimers or heterodimers 
with its homologues APLP-1 and -2 (Soba et al., 2005).
While single gene knock out mice for APP, APLP-1 or APLP-2 show only mild phenotypes, 
double knockout models (APP/APLP-2; APLP-1/APLP-2) are lethal, showing that the APP pro-
tein family plays important physiological roles, that are partly redundant (Zheng et al., 1995; von 
Koch et al., 1997; Heber et al., 2000). Particularly the Aβ domain, which consists of  the last 28 aa 
of  the APP ectodomain and the first 12-14 aa of  the tm-domain and is not present in APLPs, 
cannot play a pivotal physiological role. However, a recent study demonstrates a ferroxidase activ-
ity of  APP and a role in neuronal iron-export. Intracellular iron accumulates in primary neurons 
of  APP knock  out  mice.  Moreover,  APP knock  out  mice  fed  with  an  iron  dietary  exhibit 
increased Fe2+ levels, resulting in oxidative stress in cortical neurons (Duce et al., 2010).
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 1.1.4 APP processing
The release of  Aβ from APP is mediated by two different proteases. These so-called secretases 
cleave APP sequentially in the lumen of  cellular organelles e.g. Golgi, endosomes and lysosomes 
or at the cell surface. The first cleavage is catalyzed by β-secretase at position 1 of  the Aβ domain 
(see fig. 2 and 3), thereby releasing the soluble APP fragment (sAPPβ) and a membrane bound C-
terminal fragment (CTF) with a size of  99 aa (CTFβ or C99). Further processing of  CTFβ by a 
multienzyme complex called γ-secretase leads to the production of  Aβ and the release of  the 
APP intracellular domain (AICD) into the cytosol (Haass et al., 1992b; Sastre et al., 2001; Haass 
& Steiner 2002). Since γ-secretase can cleave C99 at different sites, several Aβ variants with sizes 
of  37 aa–42 aa arise. However, Aβ40 (~90 %) and Aβ42 (~10 %) are the variants most frequently 
released from the membrane  (Citron et al.,  1996;  Weggen et al.,  2001; Wiltfang et  al.,  2002). 
Importantly,  Aβ42 is,  based on its hydrophobicity,  most prone to aggregate and form plaques 
(Barrow & Zagorski 1991; Jarrett et al., 1993).  Alternatively, APP can be processed in the non 
amyloidogenic pathway which results in the generation of  a small, non amyloidogenic peptide, 
named p3. In this pathway the first cleavage of  APP within the Aβ domain at aa 16 (see fig. 2 and 
11) is catalyzed by the α-secretase (Esch et al., 1990; Sisodia et al., 1990) releasing sAPPα into the 
extracellular space and a CTF which is 83 aa in size (CTFα or C83).
The subsequent γ-secretase cleavage of  CTFα results in the release of  the non amyloidogenic p3 
peptide (Haass et al., 1993; Sastre et al., 2001) and AICD, like in the amyloidogenic pathway. The 
Figure 2: Scheme of  the APP structure.
APP can be divided in a large extracellular ectodomain,  a short  single  transmembrane (tm)-domain and a 
cytosolic tail. The Aβ domain (dark gray) is located at the end of  the ectodomain and the beginning of  the 
transmembrane domain. The box highlighted the Aβ and tm-domain as amino acid sequence. The cleavage site 
of  the three secretases are indicated by arrows. Modified from “Cellular processing of  β-amyloid precursor 
protein and the genesis of  amyloid β-peptide” (Haass & Selkoe 1993).
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AICD was shown to have gene regulatory function (Cao & Sudhof  2001; Kimberly et al., 2001; 
Alves da Costa et al., 2006), but other groups could not confirm these findings (Hass & Yankner 
2005; Hebert et al., 2006). However, a recent paper demonstrates a function for the sAPPβ frag-
ment as ligand for the death receptor 6 which is involved in axonal pruning and neuronal cell 
death (Nikolaev et al., 2009).
 1.1.5 Structural and functional insights in the APP processing enzymes
 1.1.5.1 The α-secretase: ADAM-10, ADAM-17 and ADAM-9
All proteases which catalyze the cleavage of  ectodomains are called sheddases. The main APP 
ectodmomain shedding in non-neuronal cells occurs by α-secretase cleavage between K16 and 
L17 of  the Aβ region. There are three enzymes of  the ADAM (a disintegrin and metalloprotease) 
protease family which were identified to have α-secretase properties: ADAM-10 (Lammich et al., 
1999), ADAM-17 also known as tumor necrosis factor-α converting enzyme  (Buxbaum et al., 
1998) and ADAM-9 (Koike et al., 1999). Interestingly, the overexpression of  ADAM-10 in mice 
increased α-secretase cleavage thereby lowering Aβ production (Postina et al., 2004). Moreover, 
Figure 3: The APP processing.
In the amyloidogenic pathway APP is first cleaved by β-secretase generating sAPPβ and CTFβ. In the non-
amyloidogenic pathway α-secretase cleaves first within the Aβ domain, thereby generating sAPPα and CTFα. 
The subsequent cleavage of  the CTFs by γ-secretase results in the release of  Aβ in the amyloidogenic and of  
p3 in the non-amyloidogenic pathway. Modified from “Cellular processing of  β-amyloid precursor protein and 
the genesis of  amyloid β-peptide” (Haass & Selkoe 1993). 
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the ectodomain shedding of  APP can be increased by activation of  protein kinase C (Etcheber-
rigaray et al., 2004).
All ADAMs are type I transmembrane zinc metalloproteases and cleave APP on the secretory 
pathway from the trans Golgi network (TGN) to the plasma membrane or directly at the plasma 
membrane (Haass et al., 1992a; Sisodia 1992; Chyung & Selkoe 2003). During the past years the 
ADAM family appeared to be one of  the most important groups of  sheddases, with several sub-
strates involved in various signaling pathways. In addition to APP, the type I transmembrane pro-
teins  TNFα,  the  Notch  receptors,  p75,  TNFα-receptor  and  L-selectin  are  substrates  of  the 
ADAM family (Seals & Courtneidge 2003). Mice deficient for either ADAM-10 or ADAM-17 are 
lethal already in embryonic state, confirming the important physiological role of  these sheddases 
(Peschon et al., 1998; Hartmann et al., 2002).
 1.1.5.2 The β-secretase: BACE-1
The shedding of  the APP ectodomain is essential for the release of  Aβ, but for a long time the 
exact protein acting as β-secretase was unknown. In the late '90s a type I transmembrane aspartyl 
protease,  the  β-site  APP cleaving  enzyme-1 (BACE-1),  also  known as  aspartic  protease-2  or 
memapsin-2 (membrane-associated aspartic protease-2) could be identified as β-secretase  (Hus-
sain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000). Like all 
type I transmembrane proteins BACE-1 consists of  an ectodomain, a transmembrane domain 
and a C-terminal cytosolic tail (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et 
al.,  1999;  Lin et  al.,  2000).  The ectodomain bears the  typical  DTGS and DSGT amino acid 
motifs, forming the catalytic center of  aspartyl proteases (Hussain et al., 1999; Vassar et al., 1999; 
Yan et al.,  1999). Mutation of  one of  these motifs abolishes the protease activity completely 
(Hussain et al., 1999).
As other aspartic proteases, BACE-1 contains a propeptide, located at the N-terminus of  the 
enzyme, which is  cleaved during  maturation by furin or  a  furin-like  protease  (Bennett  et  al., 
2000b; Capell et al., 2000; Creemers et al., 2001). Furthermore, the ectodomain contains four 
asparagine residues which undergo complex N-glycosylation during the transport from the ER to 
the Golgi (Capell et al., 2000; Huse et al., 2000). Fully matured BACE-1 is transported from the 
Golgi to the cell surface. The transport of  BACE-1 is mediated by motifs located in the cytoplas-
mic domain, since the deletion of  this part results in an accumulation of  BACE-1 in the ER 
(Capell et al., 2000). From the cell surface, BACE-1 can be re-internalized into endosomal com-
partments from which it is either recycled back to the plasma membrane or transported to the 
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TGN (Walter et al., 2001a) or lysosomes (Koh et al., 2005). While the re-internalization is medi-
ated by a di-leucine motif  in the C-terminus (Huse et al., 2000; Pastorino et al., 2002), the trans-
port to the TGN is controlled by the phosphorylation state of  the adjacent serine residue S498 
(Walter et al., 2001a). Both the di-leucine motif  and serine 498 are part of  a DISLL motif  which 
follows the structure DxxLL, known to serve as the binding site for a particular group of  trans-
port  proteins,  the  GGAs (Golgi  associated,  γ-adaptin  ear containing,  ARF binding proteins). 
These are monomeric adapter proteins which sort specific cargo-proteins like the mannose-6-
phosphate receptor from the TGN to endosomal/lysosomal compartments  (Bonifacino 2004; 
Robinson  2004).  BACE-1  was  shown  to  bind  GGAs  (He  et  al.,  2002;  Shiba  et  al.,  2004). 
Moreover, it was shown that the DxxLL motif  regulates the retrograde transport of  internalized 
BACE-1 from endosomal compartments to the TGN in a phosphorylation dependent manner 
(Wahle et al., 2005). In addition to the critical DxxLL motif, the C-terminus of  BACE-1 contains 
also three cysteine residues which can be palmitoylated (Benjannet et al., 2001). The palmitoyla-
tion leads to the insertion of  a second membrane anchor which might take part in regulating the 
subcellular localization (Schweizer et al., 1996; Vetrivel et al., 2009). Although β-secretase activity 
was detected in various cell types and tissues, the highest BACE-1 activity was measured in neur-
onal tissue, particularly in neurons (Haass et al., 1992b; Shoji et al., 1992; Seubert et al., 1993). 
Biochemical studies revealed that BACE-1 shows highest activity at pH 5 (Vassar & Citron 2000; 
Walter et al., 2001b). Accordingly, BACE-1 was mainly found in endosomal and lysosomal com-
partments.
Less is known about the physiological role of  BACE-1, since BACE-1 knock out mice show no 
overt phenotype. However, more careful analysis of  BACE-1 deficient mice revealed a decreased 
myelination, suggesting a role of  BACE-1 in the formation of  myelin sheets. Responsible for this 
defect might be the impaired cleavage of  the transmembrane protein neuregulin-1 by BACE-1 
(Aoki et al., 2004; Hu et al., 2006; Willem et al., 2006; Hu et al., 2008). Physiologically neuregulin-
1 plays a role in the maintenance of  heart function and in myelination of  axons. Other known 
BACE-1 substrates are beside APP also the APLPs  (Li & Sudhof  2004), the sialyltransferase 
ST6Gal-I (Kitazume et al., 2003), the P-selectine glycoprotein ligand-1 (PSGL-1) (Lichtenthaler 
et al., 2003) and LRP (low density lipoprotein receptor related protein) (von Arnim et al., 2005).
In parallel to BACE-1 a homologue protein was identified as β-site APP cleaving enzyme-2. Both 
proteins have similar structural organization and share more than 50 % sequence identity on the 
amino acid level (Vassar et al., 1999; Yan et al., 1999; Acquati et al., 2000; Hussain et al., 2000; Lin 
et al., 2000). Consistent with the high molecular structure identity to BACE-1, BACE-2 under-
goes  comparable  posttranslational  modifications  like  complex  N-glycosylation  at  asparagine 
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residues  located  in  the  ectodomain  (Vassar  &  Citron  2000;  Walter  et  al.,  2001b).  Immature 
BACE-2 also contains a propeptide which is cleaved during the maturation. However, while this 
maturation step is catalyzed by furin proteases in BACE-1, the propeptide of  BACE-2 appears to 
be removed autocatalytically (Hussain et al., 2001; Yan et al., 2001). Although both enzymes are 
very  similar,  BACE-2 shows striking differences regarding stability  and intracellular transport 
(Fluhrer et al., 2002). Compared to BACE-1 that is highly expressed in neurons, there is relative 
low expression of  BACE-2 in the nervous system, but higher in peripheral tissues (Vassar et al., 
1999; Bennett et al., 2000a). The highest expression in the nervous system is observed in glia cells 
(Dominguez et al., 2005). Since the bace2 gene is localized on chromosome 21, a contribution of  
BACE-2 to the AD-like pathology in Down's syndrome and in AD was suggested  (Yan et al., 
1999;  Solans et  al.,  2000;  Vassar & Citron 2000;  Walter  et  al.,  2001b).  Interestingly,  BACE-2 
mRNA and protein levels were increased in individuals with Down's syndrome (Motonaga et al., 
2002; Barbiero et al., 2003).
As shown by cell biological studies, BACE-2 is able to cleave APP, but the cleavage efficiency at 
the β-secretase site is very low (Bayer et al., 1999; Farzan et al., 2000; Hussain et al., 2000; Lin et 
al., 2000; Yan et al., 2001). Rather, BACE-2 cleaves APP in an α-secretase-like manner within the 
Aβ domain between phe 19 and phe 20 as well as between phe 20 and ala 21 (Farzan et al., 2000; 
Yan et al., 2001; Fluhrer et al., 2002). Accordingly, protein expression studies in human brain of  
AD patients and aged-matched controls, can detect BACE-2, but the expression and activity is 
not significantly altered in AD brains (Stockley et al., 2006; Ahmed et al., 2010).
 1.1.5.3 The γ-secretase
The γ-secretase is a multiprotein complex consisting of  four essential components. The catalytic 
center of  the complex is formed by PS1 or its homologue PS2 (Levy-Lahad et al., 1995; Sherring-
ton et al., 1995), supported by three additional co-factors: nicastrin (Yu et al., 2000; Edbauer et 
al., 2002b; Kopan & Goate 2002; Lai 2002), APH-1 (anterior pharynx-defective-1) (Francis et al., 
2002; Goutte et al., 2002; Lee et al., 2002; Luo et al., 2003) and PEN-2 (presenilin enhancer-2) 
(Francis et al., 2002; Steiner et al., 2002; Luo et al., 2003). These components appear in a stoi-
chiometric ratio of  1:1:1:1 in the mature γ-secretase complex (Sato et al., 2007). Since the total 
molecular mass of  the γ-secretase complex is higher than the summarized molecular masses of  
the single components, it was early considered that other unidentified proteins take part in the 
complex. In fact,  it was shown that γ-secretase modulators (GSMs) like TMP21  (Chen et al., 
2006; Pardossi-Piquard et al., 2009), CD147 (Zhou et al., 2005) and the recently found GSAP (γ-
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secretase activating protein) (He et al., 2010) are associated with the γ-secretase complex and can 
modulate γ-secretase activity. However, purification of  γ-secretase during which the GSMs are 
separated early from the rest of  the γ-secretase complex, and subsequent activity assays with the 
purified γ-secretase, revealed that GSMs are not relevant for the basal activity of  the γ-secretase 
complex. Thus, the four main components PS, nicastrin, APH-1 and PEN-2 are sufficient for an 
active γ-secretase complex (Winkler et al., 2009).
PS1 and PS2 are membrane proteins with nine transmembrane domains, bearing the two catalytic 
aspartate residues (Spasic et al., 2006). In the γ-secretase complex, presenilins are present as a het-
erodimer formed by a C-terminal and an N-terminal fragment, each of  them containing one cata-
lytic aspartate residue. The two fragments are most likely generated by autocatalytic endoproteo-
lysis between tm-domain 6 and tm-domain 7 (Ratovitski et al., 1997; Capell et al., 1998; Wolfe et 
al., 1999a; Wolfe et al., 1999b; Kimberly et al., 2000).
Nicastrin, a glycosylated type I transmembrane protein was shown to be involved in the substrate 
recognition. Nicastrin binds the extracellular/lumenal N-terminus, generated upon ectodomain 
shedding of  type I transmembrane proteins, thereby recruiting the substrate into the catalytic 
center. It was found that the recognition is not mediated by the amino acid sequence of  the sub-
strates. Only a short free N-terminal part above the cell membrane seems to be necessary (Yu et 
al., 2000; Shah et al., 2005).
PEN-2 and APH-1 are both polytopic transmembrane proteins. Only little is known about the 
function of  these proteins. However, PEN-2 is supposed to support the endoproteolytic cleavage 
of  presenilin, because PEN-2 deficiency stabilized the presenilin holoprotein (Hu & Fortini 2003; 
Luo et al., 2003; Takasugi et al., 2003; Prokop et al., 2004). Although the assembly of  the whole 
γ-secretase complex is not yet fully understood, there is evidence that APH-1 supports this pro-
cess and is involved in maturation and transport (Luo et al., 2003; Takasugi et al., 2003; Kaether 
et al., 2006a). There are studies showing that only fully assembled complexes can be transported 
via the secretory pathway to the plasma membrane and early endosomes where most of  the γ-
secretase is located (Walter et al., 1998; Annaert et al., 1999; Kaether et al., 2006a), while unas-
sembled, single components were retained in the ER (Kaether et al., 2006a; Dries & Yu 2008).
To date a couple of  different γ-secretase substrates are identified. Among these are APP, Notch 
(De Strooper et al., 1999; Saxena et al., 2001) and other proteins which have important physiolo-
gical functions e.g. APLP-1 and -2  (Walsh et al., 2003), E- and N-cadherin  (Marambaud et al., 
2002), EphB (Georgakopoulos et al., 2006) and LRP (May et al., 2002). Another important pro-
tein  which  is  processed  by  γ-secretase  is  the  widely  expressed  cell-adhesion  protein  CD44 
(Okamoto et al., 2001; Lammich et al., 2002; Murakami et al., 2003), implicated amongst others in 
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leukocyte homing and activation as well as cell migration.
Since the cleavage reaction occurs in all cases inside the plasma membrane and not in a water 
containing  environment,  the  process  is  called regulated intramembrane  proteolysis  (RIP).  To 
afford proteolysis within the membrane, it was suggested that the γ-secretase complex forms a 
water containing pore in which the cleavage reaction is catalyzed. Because of  the high number of  
γ-secretase substrates and its less cleavage specificity, the γ-secretase was long time assumed to be 
a  “proteasome of  the membrane”  (Kopan & Ilagan 2004).  However,  an unbiased proteomic 
screen revealed exact substrate characteristics, as the short ectodomain and permissive transmem-
brane and cytoplasmic domain  (Hemming et al., 2008). Besides the release of  gene regulatory 
intracellular  domains,  like  the  Notch ICD  (De Strooper  et  al.,  1999;  Saxena  et  al.,  2001),  γ-
secretase can directly affect the Wnt signaling pathway by direct interaction with GSK3β and β-
catenin (Prager et al., 2007). PS1 mediated processing of  Notch, which is involved in transcrip-
tional regulation of  developmental genes is a crucial function of  γ-secretase. Because of  this 
PS -/- mice and PS1/PS2 knockout mice resemble a Notch knock out phenotype to some extent, 
and are lethal directly after birth (Shen et al., 1997). However, PS2 -/- mice are viable, indicating 
that PS2 could not compensate PS1 deficiency.
There is evidence that γ-secretase function is also important for endocytosis. In presenilin defi-
cient cells the endocytosis of  the LDL-receptor is impaired, leading to upregulation of  choles-
terol biosynthesis (Tamboli et al., 2008).
Recently, a very interesting function of  γ-secretase in neurogenesis was published. Neural pro-
genitor cells (NPCs) from mice expressing a variant of  presenilin linked to familiar AD (PS FAD) 
show a  defect  in  proliferation  (Choi  et  al.,  2008).  Moreover,  NPCs cultured  in  medium of  
microglia  from PS  FAD mice  exhibit  a  significant  less  proliferation  rate  than  the  NPCs  in 
medium of  control microglia. Based on these results a non-cell-autonomous mechanism was sup-
posed by which γ-secretase modulates neurogenesis (Choi et al., 2008). In a subsequent study the 
authors could show that microglia from PS1 FAD mice produce altered chemokine levels and 
that these chemokines are closely linked to neurogenesis (Veeraraghavalu et al., 2010). Although 
γ-secretase expression was mainly shown in neurons.  These results give the first  hints  for γ-
secretase function in microglia.  According to this, the presence of  presenilin and nicastrin in 
microglia and reactive astrocytes following traumatic brain injury (Nadler et al., 2008) might be 
related to the modulation of  neurogenesis.
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 1.2 Aβ clearance in the brain
While EOAD is predominantly caused by increased Aβ42/Aβ40 ratio or altered aggregation beha-
vior of  Aβ, the reasons for developing sporadic AD are largely unclear. Most likely, a misregula-
tion of  either Aβ production, Aβ clearance or both could contribute to sporadic pathogenesis. In 
fact, the activity of  BACE-1 which catalyzes the rate limiting step in the generation of  Aβ is 
increasing with age in humans (Tyler et al., 2002; Kern et al., 2006; Stockley et al., 2006) as well as 
in mice  (Apelt et al., 2004). In contrast, the amount and activity of  Aβ degrading enzymes is 
reduced with age (Wang et al., 2006). Moreover, there are findings that the ability of  microglia to 
clear Aβ decreases also with age (Hickman et al., 2008).
There are different pathways by which Aβ can be cleared from the brain:
Efflux of  soluble Aβ to the peripheral circulation through the blood brain barrier.
The blood brain barrier (BBB) is a highly specialized endothelial structure of  the brain cells, sep-
arating together with astrocytes, pericytes and microglia components of  the blood stream from 
neurons (Zlokovic 2008). To clear sAβ from the brain, it can be transported across the BBB into 
brain blood vessels by LRP1 mediated transcytosis  (Shibata et  al.,  2000;  Deane et al.,  2008b; 
Deane et al., 2009). Therefore sAβ either binds directly (Deane et al., 2004) or in complex with 
ApoE (DeMattos et al., 2004; Bell et al., 2007; Deane et al., 2008a) or α2-macroglobulin (Narita et 
al., 1997; Qiu et al., 1999) to LRP-1, located on brain endothelial cells. A relatively minor part 
(10-15 % of  total  Aβ clearance) is  directly  transported by bulk flow of  interstitial  fluid into 
cerebrospinal fluid, followed by drainage into the blood stream (Shibata et al., 2000; Deane et al., 
2009). Furthermore, there is an active transport of  Aβ across the BBB, mediated by the P-gly-
coprotein efflux pump, highly expressed on the lumenal surface of  brain capillary endothelial 
cells (Lam et al., 2001; Cirrito et al., 2005; Kuhnke et al., 2007).
Proteolytic degradation of  Aβ.
sAβ has been shown to be sensitive to proteolytic  degradation mediated by proteases  which 
cleave  Aβ  additionally  to  their  physiological  substrates.  The  known  proteases  are  neprilysin 
(NEP), insulin degrading enzyme (IDE), endothelin converting enzyme-1 (ECE1), angiotensin 
converting enzyme (ACE), plasmin and matrix metalloprotease-9 (MMP9) (Miners et al., 2008). 
With respect to Aβ degradation, NEP and IDE are the best characterized intracellular and extra-
cellular enzymes in microglia and other cells (Iwata et al., 2000; Mukherjee & Hersh 2002; Jiang et 
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al., 2008).
NEP is a type II transmembrane protein of  the zinc metalloprotease family, so its C-terminal 
domain is oriented to the extracellular space (Malito et al., 2008). NEP is able to degrade sAβ in 
the extracellular space while Aβ40 can be degraded more efficiently than Aβ42. There are several 
studies supporting the role of  NEP as a rate-limiting Aβ degrading enzyme. NEP knockout in 
mice results in decreased degradation of  injected radiolabeled Aβ as well as suppression of  endo-
genous Aβ levels (Iwata et al., 2001). Furthermore, overexpression of  NEP (8-fold) in APP trans-
genic mice revealed a 50 % decrease of  soluble and insoluble Aβ40 and Aβ42 (Leissring et al., 
2003).
IDE is also a zinc metalloprotease which is normally expressed in the cytosol of  microglia, neur-
ons and astrocytes but can be also found membrane localized or as a secreted protein. Microglia 
and astrocytes were found to secrete IDE (Malito et al., 2008) via an exosome mediated pathway, 
since IDE lack any signal sequence (Bulloj et al., 2010; Tamboli et al., 2010). In addition to insulin 
and numerous other substrates, sAβ has been reported to be a canonical substrate of  IDE. The 
strongest evidence that IDE can indeed degrade sAβ has come from studies with IDE -/- and 
IDE +/- mice. While homozygous mice showed < 50 % increased Aβ levels compared to controls, 
heterozygous mice exhibit Aβ levels that were intermediate between the IDE -/- and the control 
mice (Farris et al., 2003). Further support came from the overexpression experiments of  Leiss-
ring and colleagues as described already for NEP. In this study a 2-fold overexpression of  IDE 
resulted in a 50 % decrease of  Aβ (Leissring et al., 2003), suggesting that IDE is the more effi-
cient Aβ degrading enzyme. Interestingly, the levels of  IDE were found to be elevated in an AD 
mouse model, overexpressing APPswe  and PS1 ∆exon 9  (Lazarov et al., 2005). However, it was 
also reported that levels of  NEP, IDE and MMP9 were massively reduced in older mice concom-
itant with the upregulation of  pro inflammatory cytokines (Hickman et al., 2008).
Uptake and degradation by microglia
Microglia were shown to internalize fibrillar Aβ (fAβ) and sAβ by phagocytosis and a process 
called macropinocytosis, respectively. The exact mechanisms are discussed in 1.4.1. However, by 
yet unknown mechanisms the phagocytosis efficiency of  microglia is decreased in AD (discussed 
below).
INTRODUCTION 30
 1.3 Microglia
Microglia are resident macrophages of  the central nervous system (CNS) and account for 5-10 % 
of  the total cell population in the brain. They are derived from myeloid precursors, which was 
conclusively shown by absence of  microglia in PU.1 null mice (McKercher et al., 1996), a tran-
scription factor controlling gene expression during myeloid development. These precursors enter 
the CNS during development, proliferate and mature under the influence of  the CNS microen-
vironment. In the adult brain microglia have a small cell soma, little perinuclear cytoplasm and a 
number of  fine branched protrusions (Ransohoff  & Perry 2009). By in vivo two-photon micro-
scopy of  mice expressing GFP in the gene coding for the fractalkine receptor it was shown that 
microglia in the “ramified”, also known as “resting” state are very active. The processes and 
arborization of  such cells are highly motile. De novo synthesis of  the protrusions and withdrawal 
of  the protrusions lead to permanent reorganization of  the processes (Davalos et al., 2005; Nim-
merjahn et al., 2005). Such dynamic structures enable the microglia to monitor their local envir-
onment without disturbing other cells in the CNS in particular neurons (Hanisch & Kettenmann 
2007). This distinct phenotype is maintained by intensive contact of  microglia to the cells in their 
immediate environment. A couple of  receptor-ligand pairs, which are expressed on microglia and 
their neighboring cells, play a crucial role in this process. CD200 expressed on neurons binds to 
the CD200 receptor (CD200R) located on the microglia surface (Hoek et al., 2000; Wright et al., 
2000).  CD200R contains an immunomodulatory  tyrosine  inhibitory  motif  (ITIM) that  averts 
activation of  microglia via Src activation and recruitment of  SHP-1 & 2 (Src homology region 2 
domain-containing phosphatase). Other ligand–receptor pairs which can modulate the phenotype 
of  microglia are CX3CL1–CX3CR1 (Cardona et al., 2006) and SIRPα–CD47 (Vernon-Wilson et 
al., 2000). Disruption of  these cell–cell contacts through brain injury or disease results in a shift 
of  the microglia activation state towards a phenotype characterized by shortened and extensively 
branched processes and hypertrophy of  the cell body (Perry et al., 2010). The so-called “off-sig-
naling” is only one important signaling principle which organizes the microglia responsiveness. 
The  other  principle,  the  “on-signaling”  relies  on  receptors  recognizing  pathogen-associated 
molecular  pattern  molecules  (PAMPs)  or  damage-associated  molecular  pattern  molecules 
(DAMPs). PAMPs are proteins of  microbiological origin, like lipopolysaccharide, peptidoglycan 
and nucleic acid variants associated with viruses. These molecules are recognized by different toll-
like receptors  (TLRs)  or  other pattern recognition receptors.  DAMPs are mostly  intracellular 
molecules which are released due to cell damage or cell death. Examples are heat shock proteins, 
HMGB1 (high-mobility group box 1) (Scaffidi et al., 2002), high concentrations of  ATP (Davalos 
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et al., 2005) or UDP as well as DNA. Some of  these DAMPs are also recognized by TLRs (for 
example  DNA by TLR9)  whereas  the  detection of  ATP and UDP is  accomplished by P2Y 
metabotropic receptors  (Haynes et al., 2006; Koizumi et al., 2007). Another important DAMP 
receptor expressed on microglia is the receptor for advanced glycosylated end products (RAGE). 
Detection of  PAMPs and DAMPs results in phagocytosis. The uptake of  bacterial molecules is 
thereby accompanied by release of  inflammatory-mediators (Hanisch et al., 2001; Hausler et al., 
2002) whereas microglia which engulf  apoptotic cells or myelin debris release anti-inflammatory 
factors (Magnus et al., 2001; Liu et al., 2006).
 1.4 The role of  microglia & inflammation in AD
Microglia play a multifaceted role in the pathogenesis of  AD. To date, there is a controversial 
debate  going  on  whether  they  are  beneficial  or  detrimental.  Their  beneficial  contribution  is 
mostly linked with Aβ phagocytosis, as discussed in detail in 1.4.1 whereas the detrimental effects 
are connected with amplification of  as well as response to inflammatory processes. 
In brains of  AD patients and in a well known mouse disease model the Tg2576 mouse, amyloid 
plaques are found associated with microglia, exhibiting an “activated” proinflammatory pheno-
type  (Perlmutter et al., 1990; Frautschy et al., 1998). Moreover,  in vivo two-photon microscopy 
revealed that surveying microglia rapidly extend their processes and finally migrate towards a new 
appeared plaque (Bolmont et al., 2008; Meyer-Luehmann et al., 2008). The number and size of  
microglia increase thereby in proportion to the size of  plaques, suggesting a role of  microglia in 
plaque maintenance  (Bolmont et al., 2008; Meyer-Luehmann et al., 2008; Yan et al., 2009). In 
contrast, it was shown that the ablation of  endogenous microglia in an AD mouse model has no 
effect on the plaque number and size over a period of  2-4 weeks. However, there was a 3-4 fold 
increase in soluble Aβ40 and Aβ42 measurable, meaning that microglia contribute to the removal 
of  soluble Aβ species (Grathwohl et al., 2009).
 1.4.1 Beneficial roles of  microglia in Aβ clearance
Several  cells  and pathways were described to  be  necessary for  the uptake  of  sAβ.  The best 
described one is the uptake of  sAβ by brain capillary endothelial cells in a LRP1 mediated path-
way. Although, microglia expresses LRP (Marzolo et al., 2000) it is not the major pathway for the 
uptake of  sAβ since treatment of  microglia with the LRP antagonist receptor-associated protein 
(RAP) had no effect on the sAβ uptake (Mandrekar et al., 2009). However, it was also shown that 
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intracellular degradation of  sAβ by microglia was induced in presence of  ApoE, a ligand for 
LRP1 (Jiang et al., 2008), supporting the role of  LRP1 in the microglia sAβ uptake. The receptor 
complex including scavenger receptors, CD36 and CD47 which is believed to be responsible for 
internalization  of  fAβ,  plays  no  role  in  uptake  of  sAβ because  the  inhibition  of  individual 
receptor components didn't  significantly  impair the incorporation of  sAβ in microglia  (Man-
drekar  et  al.,  2009).  In  contrast,  a  macropinocytosis  mediated uptake process  was suggested, 
where sAβ is taken up to pinocytotic vesicles which are transported rapidly to endolysosomal 
compartments where the soluble peptides undergo degradation (Mandrekar et al., 2009).
Although some studies show no effect of  microglia on plaque size, there are some findings indic-
ating  that  microglia  can  ingest  fAβ via  receptor-mediated  phagocytosis  (Paresce  et  al.,  1996; 
Koenigsknecht  &  Landreth  2004).  However,  it  is  not  conclusively  evidenced  yet,  whether 
microglia can degrade fAβ intracellularly. The findings vary from release of  fAβ after internaliza-
tion (Chung et al., 1999) to the retention of  fAβ for some weeks before degradation (Paresce et 
al.,  1997).  The degradation of  Aβ might  depend on the activation status of  microglia,  since 
microglia activated with the macrophage colony-stimulating factor were able to degrade fAβ effi-
ciently (Majumdar et al., 2007). Moreover, microglia displaying an activation status in which they 
produce  proinflammatory  cytokines,  were  unable  to  take  up  and  degrade  fAβ  (Koenig-
sknecht-Talboo & Landreth 2005).
Several receptors have been shown to interact with fAβ. Contribution of  Fc receptors (FcRs) was 
suggested, because opsonization of  Aβ with anti-Aβ antibodies in the brain of  mice resulted in a 
robust phagocytic response  (Bard et al., 2000; Wilcock et al., 2003). Additionally, TLRs  (Reed-
Geaghan et al., 2009; Stewart et al., 2010), scavenger receptors of  class A and B as well as integ-
rins play an important role in the uptake of  fAβ. All these receptors were thought to form a 
receptor complex which leads to induction of  phagocytosis subsequent to receptor activation 
(Bamberger  et  al.,  2003).  Although a lot  of  studies indicate  phagocytosis  of  Aβ  in  vitro,  the 
unsolved question remains why they fail to clear amyloid deposits in the brain.
Besides their function as phagocytes, microglia also express Aβ degrading enzymes as explained 
in 1.2, which can degrade Aβ species directly in the extracellular environment.
Furthermore, microglia can contribute to neurogenesis when they are activated by T helper cell 
cytokines like IL-4 and low concentrations of  interferon-γ (Butovsky et al., 2006).
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 1.4.2 Detrimental roles of  microglia by chronic enhancement of  inflammatory processes
Inflammation is an active defense mechanism against  diverse insults,  designed to remove the 
injurious stimuli and to inhibit or reverse their detrimental effects. Evidences that inflammatory 
processes  play a  role  in AD came initially  from epidemiological  studies showing that people 
treated with non steroidal anti inflammatory drugs (NSAIDs) over a long period of  time, have a 
reduced risk to develop AD (Andersen et al., 1995; Breitner et al., 1995). The induction of  the 
inflammatory processes is ascribed to the accumulation of  Aβ aggregates. These aggregates trig-
ger cellular stress finally resulting in cell death. The binding of  Aβ to RAGE on neurons results 
in oxidative stress and cytotoxicity  (Yan et al., 1996).  Moreover, the binding of  Aβ to various 
microglial surface receptors, like RAGE, scavenger receptors as well as TLRs and their co-re-
ceptor CD14 can activate microglia (Liu et al., 2005). Such activated microglia secrete proinflam-
matory cytokines and produce reactive oxygen species (ROS) and nitric oxide (NO) (Mantovani 
et al., 2004; Cameron & Landreth 2010). These toxic substances can augment the oxidative stress 
and neuronal loss observed in AD brains (fig. 4).
The  activation  of  the  complement  system  by  Aβ  could  further  increase  the  inflammatory 
response of  microglia and could directly attack neurons by forming membrane attack complexes 
(Rogers et al., 1992; Webster et al., 1997a; Webster et al., 1997b).
Massive cell death could then facilitate the inflammatory response of  microglia through the reac-
tion to DAMPs as explained in chapter 1.3 or by loss of  microglia-neuron contacts needed for 
microglia  suppression.  Besides  that  it  could  be  shown,  that  the  release  of  proinflammatory 
cytokines can inhibit neurogenesis (Ekdahl et al., 2003; Monje et al., 2003).
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 1.5 Triggering receptors expressed on myeloid cells (TREMs)
The triggering receptors expressed on myeloid cells (TREMs) belong to the immunoglobulin 
superfamily cell surface receptors. They are glyco-proteins of  30-40 kDa, consisting of  a single 
extracellular immunoglobulin-like domain, a single transmembrane region and a short cytoplas-
mic tail with no signal motifs (Bouchon et al., 2000). They are part of  the huge group of  type I 
transmembrane proteins. The transmembrane domain contains a charged lysine residue, import-
ant for the interaction with adapter proteins. In humans two forms of  TREMs are expressed. In 
mice homologues of  these receptors have been identified together with a third one (TREM3), 
which exists only as pseudogene in humans (Daws et al., 2001; Chung et al., 2002).
Figure 4: Scheme of  some components of  the inflammatory cascade.
A pathogenic trigger, like abnormal Aβ production and deposition elicit cellular stress and can result in dys-
function and degeneration of  neurons. Complement factors bind either to Aβ and activate microglia or directly 
attack neurons. fAβ can directly bind to TLRs thereby activating microglia. Furthermore, activation could be 
initiated by binding of  oxidized lipid via scavenger receptors. Activated microglia release ROS and NO which 
could stress neurons, starting the vicious circle again. C1qRp, C1q receptor for phagocytosis; CR3, complement 
receptor  3;  FcR,  Fc  receptor;  PSR,  phosphatidyl  serine  receptor;  SR,  scavenger  receptor.  Modified  from 
“Inflammation in Neurodegenerative Disease—A Double-Edged Sword” (Wyss-Coray & Mucke 2002). 
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 1.5.1 TREM1
TREM1 was the first receptor found of  this family and was initially cloned by a cDNA screening 
from human natural killer cells (Bouchon et al., 2000). TREM1 is mainly expressed on blood 
neutrophils and monocytes/macrophages. Activation of  the receptor by a yet unknown ligand 
and engagement with its adapter protein DNAX activating protein of  12 kDa (DAP12) triggers 
the generation of  proinflammatory cytokines like interleukin-8 (IL-8), monocyte chemo attract-
ant protein 1 (MCP1), MCP3 and macrophage inflammatory protein-1α (MIP1α) (Bouchon et al., 
2000; Bleharski et al., 2003; Colonna & Facchetti 2003), but doesn't induce phagocytosis (Ble-
harski et al., 2003). Furthermore, TREM1 is highly expressed by neutrophils infiltrating tissues 
that are infected with bacteria or fungi as well as epithelial cells in these tissues (Bouchon et al., 
2001a). According to this, the DAP12/TREM1 receptor system plays a crucial role in the ampli-
fication of  inflammatory processes caused by infection. 
 1.5.2 TREM2
TREM2 was originally identified on monocyte-derived dendritic cells (DCs), where it promotes 
migration (Bouchon et al., 2001b).  However, as TREM2 has not yet been detected on primary 
DCs, the involvement in DC biology remains unclear  (Klesney-Tait et al., 2006).  In contrast, it 
has clearly been showed that TREM2 is negatively regulating the response of  macrophages to 
TLR activation. The concentrations of  inflammatory cytokines like tumor necrosis factor (TNF) 
and IL-6 are exaggerated in macrophages of  TREM2 deficient mice (Turnbull et al., 2006) as well 
as after knockdown of  TREM2 by small interfering RNAs (siRNA)  (Hamerman et al., 2006). 
Insight into two more functions of  TREM2 was gained by studies of  the rare genetic disorder, 
polycystic  lipomembraneous  osteodysplasia  with  sclerosing  leukoencephalopathy  (PLOSL  or 
Nasu-Hakola disease). Patients exhibit multiple bone cysts and develop a progressive presenile 
dementia in the fourth decade of  life. In the white matter of  brains of  autopsied patients scler-
otic lesions including activated microglia were identified (Kitajima et al., 1989; Verloes et al., 1997; 
Tanaka 2000). Genetic analysis revealed that loss of  function mutations in the TREM2 gene and 
in the gene for the adapter protein DAP12 are causative for this disease (Paloneva et al., 2000; 
Paloneva et al., 2002). It was shown that TREM2 and DAP12 are involved in the genesis of  
osteoclasts which are multinucleated cells  of  myeloid origin involved in bone resorption and 
homeostasis.  Peripheral  mononuclear  blood  cells  from TREM2 or  DAP12  deficient  PLOSL 
patients failed to differentiate into osteoclasts  (Paloneva et al.,  2003). However, these findings 
from humans could not be reproduced in TREM2 deficient mice, so the function of  TREM2 in 
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osteoclastogenesis remains unclear. The finding that TREM2 mutations can also cause early-on-
set dementia without bone cysts,  suggests that TREM2 is active in the CNS  (Chouery et al., 
2008). Indeed TREM2 was found by  in situ  hybridization to be expressed in microglia, but the 
levels of  expression and the percentages of  expressing cells vary in different brain regions. The 
highest  percentages  were  found  in  cortical  regions  (Schmid  et  al.,  2002).  The  receptor  is 
expressed at the cell surface but predominantly distributed into two pools: one in the Golgi com-
plex and one population in exocytic vesicles, which are continuously shuttling to and from the 
cell surface  (Sessa et al., 2004). Activation of  TREM2 in microglia induces the expression of  
chemokine receptors and cell migration. Additionally,  a decrease in phagocytosis of  apoptotic 
neurons was observed after knockdown with siRNA  (Takahashi et al.,  2005; Takahashi et al., 
2007). Interestingly, this knockdown resulted in an upregulation of  inflammatory cytokines, sug-
gesting an anti-inflammatory function (Takahashi et al., 2007). Since the ligand(s) for TREM2 are 
still unknown it was unclear how TREM2 recognizes apoptotic cells, till Hsieh et al. described a 
ligand expressed on apoptotic  neurons  (Hsieh et  al.,  2009).  Another  endogenous  ligand was 
described as heat shock protein 60 (Hsp60) a mitochondrial chaperon which can be released from 
both healthy and dying cells  (Stefano et al., 2009). Moreover, other potential binding partners 
have been reported, like polyanionic microbial products such as LPS or peptidoglycan (Daws et 
al., 2003). This was supported by the finding that TREM2 can bind several species of  bacteria 
and fungi  (Daws et al., 2003) and that TREM2 can serve as an phagocytic receptor for these 
microbes  (N'Diaye et al., 2009). Nevertheless, specific molecules mediating the activation have 
not been identified. One possible explanation could be that TREM2 participates in a multimeric 
receptor complex, containing TREM2, a ligand, DAP12, plexin-A1 – a receptor known to con-
trol axon guidance – and the plexin-A1 ligand semaphorin 6D (Takegahara et al., 2006; Ford & 
McVicar 2009). However, in all scenarios DAP12 is indispensable for the function of  TREM2.
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 1.6 DAP12 – structure and signaling
DAP12 is a small signaling protein with a molecular mass of  ~12 kDa, expressed in myeloid and 
NK cells. It is composed of  a small extracellular part (~14 aa) that contains a cysteine residue to 
facilitate the formation of  homodimers through disulfide bonds, followed by a transmembrane 
region and a cytosolic domain (Lanier et al., 1998), so DAP12 belongs like TREM2 to the type I 
transmembrane  proteins.  The  transmembrane  region  contains  a  charged  amino  acid  residue 
(aspartic acid) that allows electrostatic interaction with associated receptors like TREM2 (see fig. 
5). The cytosolic domain embeds the conserved signaling element, the so-called immunoreceptor 
tyrosine-based  activation  motif  (ITAM).  The  ITAM  itself  consists  of  a  highly  conserved 
sequence D/E XX Y XX L/I(X6-8) Y XX L/I (Reth 1989) which is essential for the signaling of  
Figure 5: General understanding of  the TREM2/DAP12 signaling pathway.
Ligand binding to TREM2 leads to engagement with the ITAM motif  containing adapter protein DAP12 via 
the charged amino acid residues in the transmembrane domains of  the two proteins. Phosphorylation of  the 
two tyrosine residues in the ITAM domain, recruits the spleen tyrosine kinase (Syk), leading to activation of  
this kinase. The final downstream effects like negative regulation of  inflammatory processes in macrophages, 
the activation of  phagocytosis in microglia and the regulation of  osteoclastogenesis are the result of  a phos-
phorylation cascade of  several proteins initiated by Syk. Modified from “The TREM receptor family and signal 
integration” (Klesney-Tait et al., 2006).
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DAP12 containing receptor complexes. Besides DAP12 there are more adapter proteins known 
which signal via an ITAM domain. However, the general signaling pathway is similar for all of  
these proteins. The binding of  a ligand leads to the clustering of  the receptor e.g. TREM2 with 
DAP12. As a result, Src-family kinases become activated by dephosphorylation of  their regulat-
ory  C-terminal  tyrosine  and  subsequently  phosphorylate  DAP12 at  the  two tyrosines  in  the 
ITAM domain thereby recruiting the spleen tyrosine kinase (Syk) in myeloid cells or the Zeta-
chain associated kinase of  70 kDa (Zap-70) in NK cells. Interaction of  the kinase Src homology 
2 (SH2) domains with the phosphorylated tyrosine residues induces the activation of  the kinases. 
They  in  turn phosphorylate  several  downstream substrates  forming signaling  complexes that 
communicate to a number of  pathways in the cell, like mitogen-activated protein kinase (MAPK) 
or  phospholipase  Cγ  (PLCγ)  leading  to  different  cellular  responses  (fig.  5),  for  review  see 
(Hamerman et  al.,  2009;  Mocsai  et  al.,  2010).  The  exact  member  of  the  Src-family  kinases 
involved in the DAP12/TREM2 signaling in microglia is unknown. Mutations of  either ITAM or 
the SH2 domains in the kinases completely block the signaling function, showing that both are 
absolutely  necessary  for  the  function  of  the  associated  immunoreceptors  (Hamerman et  al., 
2009). It is known that DAP12 can mediate either activatory or inhibitory processes. The regula-
tion of  multinucleated giant cell formation (Helming et al., 2008), osteoclast fusion and the initi-
ation of  phagocytosis are three examples for an activatory signaling (see  1.5.2). The inhibitory 
signaling is generally observed when cells are stimulated simultaneously by a DAP12-associated 
receptor  and  a  distinct  receptor  system,  like  TLRs.  DAP12  deficient  macrophages  produce 
increased levels of  inflammatory cytokines after stimulation of  TLRs (Hamerman et al., 2005). 
As previously described for TREM2, DAP12 negatively regulates the transcription of  genes cod-
ing for TNF, IL-1β and inducible nitric oxide-synthase (iNOS) (Takahashi et al., 2005). DAP12 
signals  not  only  in  concert  with  immunoreceptors,  also  a  signaling  with  integrins  has  been 
described. The interaction of  DAP12 with the microglial CD11b integrin for example regulates 
neuronal  apoptosis  during  development.  Since  the  TREM2/DAP12  system regulates  several 
functions in microglia, it is interesting to study this regulation in context to AD.
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 1.7 Rationale
Microglia have been shown to phagocytose Aβ in a FcR-mediated process upon passive immun-
ization with anti-Aβ antibodies (Bard et al., 2000; Bacskai et al., 2002; Wilcock et al., 2003) as well 
as active immunization with Aβ42 (Schenk et al., 1999). However, phagocytosis of  Aβ without 
vaccination appears to be less efficient. The reason for this defect remains unclear. Since phago-
cytosis is a specific form of  endocytosis and γ-secretase has been shown to regulate endocytosis 
(Tamboli et al., 2008), a contribution of  γ-secretase in phagocytotic processes might be possible. 
There are some studies suggesting expression of  γ-secretase components in microglia. However, 
a function of  γ-secretase in these cells is still unknown.
Thus, the main goal of  this project was to investigate the expression and function of  γ-secretase 
in microglia.  By pharmacological and genetic approaches it  should also be tested whether γ-
secretase is functionally involved in phagocytosis.
One potential candidate might be the microglial receptor TREM2. As type I transmembrane pro-
tein  TREM2 might  represent  a  γ-secretase  substrate.  Since  TREM2 has  been  shown  to  be 
involved in phagocytotic processes of  apoptotic neurons in the brain, processing of  this receptor 
might alter phagocytosis of  Aβ by microglia.
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 2 MATERIAL & METHODS
Except as noted otherwise, all chemicals used for the described experiments were purchased with 
a purity grade of  “per analysi” from Sigma-Aldrich (Steinheim, Germany), Roche (Basel, Switzer-
land), Roth (Karlsruhe, Germany) or Applichem (Darmstadt, Germany). The specific cloning 
primers were obtained from Sigma-Aldrich,  and the restriction enzymes from Fermentas  (St. 
Leon-Rot, Germany).  The radiochemicals were from Hartmann Analytic (Braunschweig, Ger-
many).  Cell  culture media and additives were purchased from Invitrogen,  cell  culture plastics 
from Corning.
Table 1: Equipment
Cell culture equipment
-80 °C Freezer Thermo
Cell culture hood Thermo
37 °C CO2 incubator Binder
Water bath Medigen
Centrifuge (5804) Eppendorf
Blotting- and cloning equipment
Protein-electrophoresis chamber Höfer
Blotting chamber Höfer
Chemiluminescence Imager (ChemiDoc XRS)
with software Quantity One
Bio-Rad
Cooling system (E100) Lauda
DNA-electrophoresis chamber Amersham
Trans-UV illuminator (GVM 20) Syngene
General laboratory devices
Microcentrifuge(5415D) Eppendorf
refrigerated Microcentrifuge (5415R) Eppendorf
refrigerated Centrifuge (5804R) Eppendorf
Cycler (Mastercycler Personal) Eppendorf
Gradientcycler (Mastercycler Gradient) Eppendorf
37 °C incubator Binder
Autoclave H+P
Heeting Block (SBH 130 D) Stuard Scientific
Magnetic stirrer Velp Scientifica
pH Meter (MP 225) Mettler Toledo
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Photometer (Genesis) Thermo
Sonifier (Sonopuls, UW 2070) Bandelin
Thermomixer (Thermomixer compact) Eppendorf
Overhead rotor Scientific Industries
Vortex (MS 2 Minishaker) IKA
Analytical Balance (Labstyle 204) Mettler Toledo
Balance (PL 202-S) Mettler Toledo
Microtiterplate Reader (Multiskan RC) Thermo
Special devices
Fluorescence microscope (AxioVert 200)
with software AxioVision
Zeiss
Phosphoimager Fuji
 2.1 Cell biological techniques
 2.1.1 Cell culture 
Cell culture medium (DMEM +/+)
Dulbecco´s Modified Eagle´s Medium (DMEM) GlutamaxTM containing 4.5 g/l D-glucose supplemented with 10 % heat inactivated fetal calf  
serum (FCS) and 1 % PenStrep solution (50 U/ml Penicillin, 50 µg/ml Streptomycin)
Phosphate Buffered Saline (PBS)
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Trypsin-EDTA Solution
0.05 % (w/v) trypsin (Invitrogen), 0.53 mM EDTA, dH2O
Cryo medium
90 % FCS supplemented with 10 % dimethylsufoxide (DMSO)
Frozen cells  were  rapidly  thawed in  a  water  bath.  Cells  were  washed once  with  cell  culture 
medium (300 x g, 3 min) and plated on a new dish in fresh cell culture medium. Cells were main-
tained in a CO2 incubator at 37 °C, 95 % humidity and 5 % CO2. When cells reached confluence 
of  70-90 %,  they  were  split.  Cells  were  therefore  washed  once  with  PBS  before  they  were 
detached from the surface by 1 ml of  Trypsin-EDTA solution per 10 cm dish and plated onto a 
new culture dish in a ratio of  1:20-1:2. If  an exact cell number was needed, cells were counted in 
a Neubauer counting-chamber. For cryo conservation cells of  a 90 % confluent 6 cm dish were 
detached as described above, pelleted (300 x g, 3 min), resuspended in 1-2 ml cryo medium and 
finally stored in a -80 °C freezer or for long term storage in liquid nitrogen.
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Table 2: Cell lines
Cell line species/cell type Media and Constituents
HEK 293 human embryonic kidney cell DMEM GlutamaxTM containing 4.5 g/l D-Glucose sup-
plemented  with  10 % heat  inactivated  fetal  calf  serum 
(FCS), 50 U/ml Penicillin, 50 µg/ml Streptomycin
HEK 293 PS1 WT human embryonic kidney cell
stably expressing hPS1 WT
like HEK 293 + 100 µg/ml Zeocin
HEK 293 PS1 DN human embryonic kidney cell
stably expressing hPS1 DN
like HEK 293 + 100 µg/ml Zeocin
HEK 293 PS1 L166P human embryonic kidney cell
stably expressing hPS1 L166P
like HEK 293 + 100 µg/ml Zeocin
HEK 293 PS1 M146L human embryonic kidney cell
stably expressing hPS1 M146L
like HEK 293 + 100 µg/ml Zeocin
HEK 293 PS1 ∆Ex9 human embryonic kidney cell
stably expressing hPS1 ∆Ex9
like HEK 293 + 100 µg/ml Zeocin
HeLa human cervical cancer cells DMEM GlutamaxTM containing 4.5 g/l D-Glucose sup-
plemented  with  10 % heat  inactivated  fetal  calf  serum 
(FCS), 50 U/ml Penicillin, 50 µg/ml Streptomycin
COS-7 monkey kidney cells DMEM GlutamaxTM containing 4.5 g/l D-Glucose sup-
plemented  with  10 % heat  inactivated  fetal  calf  serum 
(FCS), 50 U/ml Penicillin, 50 µg/ml Streptomycin
ESdM mouse microglia-like cell line 
derived from embryonic stem 
cells  
DMEM/F12  (1:1)  supplemented  with  1 %  N2 
Supplement, 50 U/ml Penicillin, 50 µg/ml Streptomycin, 
0.153 % Glucose, 0.48 mM glutamine
BV-2 mouse microglia cell line DMEM/F12  (1:1)  supplemented  with  1 %  N2 
Supplement, 50 U/ml Penicillin, 50 µg/ml Streptomycin, 
0.153 % Glucose, 0.48 mM glutamine
 2.1.2 Cell culture of  ES cell derived microglia
Cell culture medium
DMEM/F12 (1:1) supplemented with 1 % N2 Supplement, 50 U/ml Penicillin, 50 µg/ml Streptomycin, 0.153 % Glucose, 0.48 mM glutamine
Cryo medium
90 % FCS supplemented with 10 % dimethylsufoxide (DMSO)
The cells (provided by Prof. Neumann,  Institute of  Reconstructive Neurobiology, Bonn) were 
thawed as described in 2.1.1 and plated on a 10 cm dish in fresh cell culture medium. Since these 
cells only proliferate to low densities, they were split at a confluence of  60-70 %. For splitting, 
cells were scraped off  with a cell scraper and plated to a new dish in a 1:3-1:5 ratio. For cryo con-
servation cells  of  a  70 % confluent 10 cm dish were detached by scraping, pelleted (300 x g, 
5 min), resuspended in 2-3 ml cryo medium and finally stored in liquid nitrogen.
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 2.1.3 Transient transfection
Opti-MEM ® I (Invitrogen)
DMEM +/-
Dulbecco´s Modified Eagle´s Medium (DMEM) GlutamaxTM containing 4.5 g/l D-glucose supplemented with 10 % FCS
Cells  were  grown  to  80 %  confluence  and  transfected  with  Lipofectamin  2000  (Invitrogen) 
according to manufacturer´s instruction (for each 6 cm dish 5 µg DNA and 7.5 µl Lipofectamin 
2000). During the transfection time of  5-6 h, cells were incubated in DMEM +/-. Medium was 
changed and cells were incubated for another 24 h at 37 °C, 5 % CO2. To achieve good transfec-
tion results the concentration of  the used DNA solution should be > 0.5 µg/ml.
 2.1.4 Immunocytochemistry (ICC)
Phosphate Buffered Saline (PBS), sterile
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
DMEM -/-
Dulbecco´s Modified Eagle´s Medium (DMEM) GlutamaxTM containing 4.5 g/l D-glucose
Poly-L-lysine solution
100 µg/ml sterile poly-L-lysine in PBS 
Distilled Water, sterile (dH2O) (Invitrogen)
Paraformaldehyde solution (PFA; 4 %)
4 % (w/v) Paraformaldehyde in PBS 
Triton X-100 solution (0.25 %)
0.25 % (v/v) Triton X-100 (Sigma-Aldrich) in PBS 
Blocking solution
10 % (w/v) BSA in PBS (for neurons: 10 % BSA in PBS + 0.25 % Triton X-100) or DMEM
Primary antibody solution
Primary antibody in appropriate concentration (see Table 7) in PBS or DMEM supplemented with 5 % BSA (for neurons: additionally with 
0.125 % Triton X-100)
Secondary antibody solution
Secondary antibody in appropriate concentration (see Table 8) in PBS or DMEM with 5 % BSA (for neurons: additionally with 0.125 % Tri-
ton X-100)
For immunocytochemistry cover slips (CS) were used which were coated with poly-L-lysine for 
1 h at 37 °C, washed three times with sterile distilled water (dH2O) and once with PBS. 150000 
cells were seeded in one 6 well (containing 3 CS). After 24 h cells were transfected as described in 
2.1.3. Cells were then washed three times with PBS and fixed in 4 % Paraformaldehyde  (Birn-
boim & Doly 1979) for 10 min. To remove residual PFA cells were washed three times with PBS. 
Cells were then permeabilized by incubation in Triton X-100 for 10 min at room temperature 
(RT) and incubated in incubated in blocking solution for 1 h at RT. The protein of  interest was 
then stained by incubation in 100 µl primary antibody solution for 1 h at RT, followed by intens-
ive washing 3 x with PBS. The washing was repeated 3 times with 5 min incubation in between. 
After incubation with secondary antibody solution (100 µl) for 1 h at RT, the unbound secondary 
antibody was removed by intensive washing as described above. Finally CS were washed once 
with dH2O and embedded on a slide with ImmuMount (Thermo). The slides were kept dark at 
4 °C. Slides were analyzed with a fluorescence microscope.
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To selectively detect cell surface proteins, cells were stained prior to fixation. For this purpose, 
cells  were  kept on ice  for  the  whole  staining procedure.  As blocking solution 10 % BSA in 
DMEM -/- was used. The primary and the secondary antibody was diluted in DMEM -/- with 
5 % BSA. All washing steps were conducted in DMEM -/-. After the last washing, the cells were 
fixed in 4 % PFA. For visualization of  the total protein expression, standard immunostaining as 
described in 2.1.4 was used.
 2.2 Molecularbiological techniques
 2.2.1 Polymerase chain reaction (PCR)
PCR reaction mix
10X Pfu Buffer with MgSO4 5 µl 
dNTP Mix, 10 mM each 1 µl (0.2 mM of  each) 
Forward primer 1.0 µM 
Reverse primer 1.0 µM 
Template DNA 10-100 ng 
Pfu DNA Polymerase 2.5 U (1 µl)
add to 50 µl total volume with nuclease-free water
The DNA constructs used in this project (see Table 3) were generated by PCR using the primers 
listed in Table 4. The PCR reaction mix was prepared on ice. For amplification the PCR program 
was run for 30 cycles after one initial DNA denaturating step (2 min, 95 °C). Every program 
included the following steps:
1. Denaturation: 95 °C, 0.5 min
2. Annealing: 50-80 °C (depends on primer), 0.5 min
3. Elongation: 72 °C, 0.5-2 min (depends on construct length)
The exact PCR programs are listed in Table 5.
The point mutations in DAP12 were generated by a three-step cloning strategy. At first two PCRs 
were conducted using the cloning primers in combination with the opposite mutation primers 
(step 1 & 2). The products of  step 1 and 2 were then used as template which was amplified using 
the cloning primers.
To continue the cloning the amplified PCR products were analyzed according to their size in a 1-
2 % agarose gel (see  2.2.2). The bands were cut out of  the gel and the DNA was isolated as 
described in 2.2.3.
MATERIAL & METHODS 45
Table 3: List of  the DNA constructs used for the project
Name Vector restriction enzymes PCR program
Flag-TREM2-mycHis pSecTag Hygro B Hind III/Xho I B2
Flag-DAP12-HA pSecTag Hygro B Hind III/Xho I B2
myc-TREM2 pSecTag Hygro B Sfi I/Hind III MutHG
DAP12-HA pSecTag Hygro B Hind III/Xho I GC
Flag-DAP12 D52A-HA pSecTag Hygro B Hind III/Xho I B2 (all three steps)
Flag-DAP12 Y92F Y103F-HA pSecTag Hygro B Hind III/Xho I Mut; B2; Mut
DAP12 Y92F Y103F-HA pSecTag Hygro B Hind III/Xho I Mut; B2; Mut
myc-TREM2-GFP pSecTag Hygro B Sfi I/Hind III MutHG
TREM2-GFP pSecTag Hygro B Sfi I/Hind III MutHG
Flag-TREM2∆ECD-mycHis pSecTag Hygro B Hind III/Xho I B2
TICD-mycHis pSecTag Hygro B Hind III/Xho I B2
Figure 6: Schematic drawings of  the different constructs used in this study.
Illustrated are the different TREM2, DAP12 and BACE constructs. The two thin blue lines indicate the mem-
brane. N- and C-terminus as well as important amino acids are highlighted. 
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Table 4: Overview of  cloning primers
Name Primer
Flag-TREM2-mycHis FW: gcgaagcttgattacaaagacgatgacgataagaacaccacggtgctg
RV: gcgctcgagtcgtacctccgggtccagtg
Flag-DAP12-HA FW: gcgaagcttgattacaaagacgatgacgataagttaagtcccgtacaggcc
RV: gcgctcgagctaaagagcgtaatctggaacatcgtatgggtatctgtaatattgcctctgtg
myc-TREM2 FW: ggcccagccggccatggcatcaatgcagaagctgatctcagaggaggacctgaacaccacggtgctg
RV: gcgaagcttttcacgtacctccgggtccagtg
DAP12-HA FW: gcgaagcttatgggggctctggag
RV: gcgctcgagctaaagagcgtaatctggaacatcgtatgggtatctgtaatattgcctctgtg
Flag-DAP12 D52A-HA FW: gcgaagcttgattacaaagacgatgacgataagttaagtcccgtacaggcc
Mut. Pr. FW: ctgggtgctttggtgttgactctgctgattgcc
Mut. Pr. RV: caccaaagcacccagaacaatcccagccag
RV: gcgctcgagctaaagagcgtaatctggaacatcgtatgggtatctgtaatattgcctctgtg
Flag-DAP12 Y92F Y103F-HA FW: gcgaagcttgattacaaagacgatgacgataagttaagtcccgtacaggcc
Mut. Pr. FW: tcgccttttcaggagcttcagggtcagagaccagaagtattcagtgac
Mut. Pr. RV: gaggtcactgaatacttctggtctctgaccctgaagctcctgaaaaggcga 
RV: gcgctcgagctaaagagcgtaatctggaacatcgtatgggtatctgtaatattgcctctgtg
myc-TREM2-GFP FW: ggcccagccggccatggcatcaatgcagaagctgatctcagaggaggacctgaacaccacggtgctg
RV: gcgaagcttcgtacctccgggtccagtg
Flag-TREM2 CTF-mycHis FW: gcgaagcttgattacaaagacgatgacgataagagcacctccaggaatcaagagacc
RV: gcgctcgagtcgtacctccgggtccagtg
B1 TMCT GFP FW: cccggatccgatgagtcaaccctcatgaccata
RV: cccctcgagtcacttcagcagggagatgtca
B2 TMCT mCherry FW: cccggatccagcaactgtgtccccgct
RV: cccctcgagtcatttccagcgatgtctgaccagaga 
B2 TMCT V513L mCherry FW: cccggatccagcaactgtgtccccgct
RV: cccctcgagtcatttccagcgatgtctgagcagaga 
B2 TMCT V513L E509D mCherry FW: cccggatccagcaactgtgtccccgct
RV: cccctcgagtcatttccagcgatgtctgagcagagaggagtcatcatt 
TICD-mycHis FW: gcgaagcttgtggccaggggcaggcag
RV: gcgctcgagtcgtacctccgggtccagtg
Table 5: Detailed PCR programs
B2 GC Mut MutHG
95 °C – 3 min 95 °C – 3 min 95 °C – 3 min
95 °C – 1 s
pause
95 °C – 3 min
95 °C – 1 min
50 °C – 1 min
72 °C – 2 min
10 x
95 °C – 0.5 min
50 °C – 0.5 min
72 °C – 1.5 min
25 x
95 °C – 1 min
50 °C – 1 min
72 °C – 3 min
30 x
95 °C – 1 min
50 °C – 1 min
72 °C – 3 min
10 x
95 °C – 1 min
60 °C – 1 min
72 °C – 2 min
20 x
72 °C – 4 min 72 °C – 5 min 95 °C – 1 min
70 °C – 1 min
72 °C – 3 min
20 x
72 °C – 7 min 72 °C – 7 min 72 °C – 5 min
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 2.2.2 Separation and visualization of  DNA fragments
TBE Buffer
9 mM Tris-Borat, 2 mM EDTA, dH2O, pH 8.0 
6 x orange loading dye
60 % Glycerin, 0.15 % Orange G, 60 mM EDTA, 10 mM Tris, dH2O, pH 7.6
GelRed (Biotium Inc.)
10000 x in water 
Agarose gels allow the separation of  DNA by their fragment length in an electric field. To separ-
ate 100-10000 bp gels of  1-2 % were used. For visualization of  the DNA the agarose gels were 
supplemented with 2 µl GelRed/100 ml gel. The DNA samples were mixed with 6 x orange load-
ing dye before they were loaded in the gel. The gel was then run in TBE buffer at 110 V. 
 2.2.3 Isolation of  DNA fragments from agarose gels
Wizard® SV Gel and PCR Clean up system (Promega)
dH2O
The desired bands were cut out of  the gel on an UV illuminator. The DNA was isolated using 
the Wizard® SV Gel and PCR Clean up system (Promega) according to the manufacturers' instruc-
tions. After elution in nuclease free dH2O, the DNA was used directly for further cloning steps.
 2.2.4 Restriction digestion
Restriction enzymes (see Table 3, Fermentas)
dH2O
Restriction digestion of  DNA was conducted in the buffer recommended for each enzyme. For 
double digestion the ideal buffer for both enzymes was chosen by the Double Digest tool available 
on the Fermentas web site. For preparative purposes 2-5 µg DNA were digested with 5-10 U of  
the appropriate enzyme in 20 µl at 37 °C for 4-16 h.
 2.2.5 Dephosphorylation of  linearized DNA
Shrimp alkaline phosphatase (SAP, 1 U/µl, Fermentas)
dH2O
To prevent self  re-ligation of  the  linearized plasmid DNA, the  free  5'-phosphate group was 
removed by adding 2 U shrimp alkaline phosphatase for the last hour directly to the restriction 
digestion.
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 2.2.6 Ligation
T4 DNA-ligase (5 U/µl, Fermentas)
dH2O
The insertion of  passenger DNA into the dephosphorylated linearized vector via the DNA-ligase 
of  the bacteriophage T4 was carried out in a molar ratio of  1:3 (vector:insert). At least 100 ng 
insert were incubated together with the reaction buffer and 5 U T4 ligase for 16 h at RT. 1/3 of  
the ligation mixture was then used for the transformation in competent E. coli cells (see 2.2.8).
 2.2.7 Generation of  chemo competent E. coli Top10
TFB I
100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2, 15 % Glycerol, pH 5.8
TFB II
10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15 % Glycerol, pH 6.8
Low salt Lauria-Bertani (LB) medium
1 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 0.5 % (w/v) NaCl, dH2O, pH 7.0 (autoclaved) 
At first, 200 ml LB medium in a 1 l flask were inoculated with 2 ml of  an overnight culture. The 
culture was incubated for 2 h under rotation (250 rpm) at 37 °C. Cells were pelleted by centrifu-
gation (1500 x g, 10 min, 4 °C). After resuspending the pellet in 30 ml ice cold TFB I by pipet-
ting, a centrifugation step followed to pellet the cells again. This pellet was then resuspended in 
4 ml ice cold TFB II. Finally, the solution was divided into 50 µl aliquots and freezed at -80 °C 
for long term storage.
 2.2.8 Transformation of  E. coli Top10
SOC medium
0.5 % (w/v) yeast extract, 2 % (w/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 20 mM MgSO4, 20 mM glucose
LB agar plates
1 % (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 15 g/l agar, dH2O, pH 7.0 (autoclaved); before pouring the plates the antibiotics 
were added to the warm (~ 40-50 °C) solution.
Selection antibiotics
Kanamycin: 30 µg/ml (Stock: 30 mg/ml, dH2O); Ampicillin: 100 µg/ml (Stock: 100 mg/ml, dH2O)
For transformation of  the chemo competent bacteria with plasmid DNA, the thawed cells were 
mixed with 1/3 of  the ligation mixture,  or in case of  re-transformation with 0.5 µg plasmid 
DNA and incubated for 30 min on ice. After a heat shock of  exact 30 s at 42 °C the cells were 
placed back on ice. 250 µl of  pre-warmed SOC medium were added to each vial and the cells 
were incubated for 1 h at 37 °C at 500 rpm in a shaking incubator. To spread the transformed 
cells  onto a  LB agar plate,  the cells  were pelleted at  300 x g for  3 min,  the supernatant  was 
removed except 50 µl. The pellet was resuspended in these 50 µl and the solution was plated on 
an agar plate supplemented with the appropriate antibiotic.
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 2.2.9 Cryo conservation of  transformed E. coli
Conservation medium
70 % (v/v) Glycerol, dH2O (autoclaved)
Low salt Lauria-Bertani (LB) medium
1 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 0.5 % (w/v) NaCl, dH2O, pH 7.0 (autoclaved) 
0.8 ml of  a fresh bacteria culture was transferred into a screw cap tube, 0.5 ml conservation 
medium was added, gently mixed and freezed at -80 °C. For  re-utilization of  the transformed 
bacteria a bit of  the frozen medium was scratched with a sterile pipette tip and transferred into a 
test tube filled with 3 ml LB medium. For an overnight culture the test tube was then incubated 
overnight (~16 h) in a shaking incubator at 37 °C and 250 rpm.
 2.2.10 Extraction of  plasmid DNA from E. coli
Resuspension buffer
50 mM Tris, 10 mM EDTA, 100 µg/ml RNase A, pH 8.0
Lysis buffer
200 mM NaOH, 1 % (w/v) SDS
Neutralization buffer
3 M Potassium acetate, pH 5.5
PureYield Plasmid Midiprep System (Promega)
GeneJET™ Plasmid Miniprep Kit (Fermentas)
For the extraction of  DNA out of  E. coli  cells an alkaline procedure was used as described by 
Birnboim & Doly (Birnboim & Doly 1979). Briefly, 1 ml of  the overnight culture was centrifuged 
(1 min, 12000 x g) and the pellet resuspended in 100 µl resuspension buffer. 100 µl lysis buffer 
were added. After mixing by inverting and an incubation of  3 min, 175 µl neutralization buffer 
were added to precipitate proteins and associated genomic DNA. Solution was cleared by centri-
fugation (10 min,  12000 x g)  and the DNA precipitated as described in  2.2.11.  The obtained 
DNA solution was used for restriction digestion (see 2.2.4).
For preparative extraction the PureYield Plasmid Midiprep System (Promega) or for small amounts 
the GeneJET™ Plasmid Miniprep Kit (Fermentas) was used. Both kits were used as described in the 
manufacturers' manual. The DNA was general eluted in nuclease-free dH2O. In case that the con-
centration of  the gained DNA solution was too low for effective transfection (2.1.3), the DNA 
was concentrated by ethanol precipitation (2.2.12).
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 2.2.11 Precipitation of  DNA by isopropanol
Isopropanol
70 % Ethanol
RNase-H2O
Sodium acetate 
3 M Sodium acetate, dH2O, pH 5.2
RNase water
RNase 10 µg/ml, dH2O
To isolate the pure DNA from the crude solution obtained from the alkaline extraction (2.2.10) 
the cleared supernatant was supplemented with 420 µl  isopropanol and 35 µl  sodium acetate. 
After a spin of  10 min at 12000 x g, the supernatant was discarded and the pellet washed with 
600 µl 70 % ethanol (EtOH). After a further spin (10 min, 12000 x g ) the pellet was air dried. 
Finally, the dried DNA pellet was resuspended in 50 µl RNase-H2O.
 2.2.12 Precipitation of  DNA by ethanol
absolute Ethanol
Sodium acetate 
3 M Sodium acetate, dH2O, pH 5.2
70 % Ethanol
Nuclease-free dH2O
To concentrate diluted DNA solutions, the DNA solution was mixed by vortexing with 1/10 
volume with sodium acetate and 3 volumes of  absolute ethanol and aliquoted to 2 ml tubes. After 
incubation for 15 min at -20 °C and a 30 min spin (12000 x g, 4 °C), the pellets were washed with 
70 % EtOH and again centrifuged (5 min, 12000 x g, 4 °C). In the end the pellets were resuspen-
ded in the required amount of  nuclease-free water to gain an applicable concentration for transi-
ent transfection (2.1.3).
 2.2.13 DNA sequencing
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems)
The  cDNA-constructs  were  sequenced  using  the  BigDye  Terminator  v1.1  Cycle  Sequencing  Kit 
(Applied Biosystems) as described in the manufacturers' guidelines.
 2.2.14 Photometric determination of  DNA concentration
The DNA was diluted 1:20 in dH2O and measured at 260 nm in a quartz cuvette (A260). The 
blank value was determined using dH2O as well. The concentration was then calculated using the 
following equation:
MATERIAL & METHODS 51
c [µg /ml ]=A260⋅dilution factor DF ⋅multiplikation factor F 
(F=50, V=20)
 2.3 Proteinbiochemical techniques
 2.3.1 Extraction of  membrane proteins out of  eukaryotic cells
Phosphate Buffered Saline (PBS)
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Hypoton buffer:
10 mM Tris, 1 mM EDTA, 1 mM EGTA, dH2O, pH 7.6 
STEN-lysis buffer:
50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) NP40 (Sigma-Aldrich), 1 % (v/v) Triton X-100 (Sigma-Aldrich), dH2O, pH 7.4
25 x Protease inhibitor (PI) cocktail 
(Complete, Roche), dH2O
Cells were washed once with PBS, scraped and pelleted in 1 ml PBS. The cells were incubated in 
0.8 ml hypoton buffer for 15 min on ice and lysed by drawing 20 x through a 0.6 mm needle. To 
clear the homogenate from nuclei and mitochondria it was spun for 10 min at 300 x g and 4 °C. 
The separation of  the cytosol fraction and the membrane vesicles was accomplished by a second 
centrifugation step (60 min, 12000 x g, 4 °C). Before the protein concentration was measured by 
the BCA assay, as described in 2.3.3, the membrane pellet was lysed in 50 µl STEN lysis buffer, 
incubated for another 15 min on ice and sedimented by a 15 min spin at 12000 x g and 4 °C. Pro-
tein extracts were either stored at -20 °C or directly used for SDS electrophoresis (see 2.3.6).
 2.3.2 Protein extraction out of  eukaryotic cells
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
RIPA lysis buffer
50 mM Tris, 150 mM NaCl, 0.5 % (w/v) Sodium deoxycholic acid, 0.1 % (w/v) SDS, 1 % (v/v) NP-40, pH 7.4 
STEN lysis buffer
50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) NP40 (Sigma-Aldrich), 1 % (v/v) Triton X-100 (Sigma-Aldrich), dH2O, pH 7.4 
Cells were washed once with PBS and lysed in 0.8 ml RIPA or STEN lysis buffer for 15 min on 
ice. The homogenates were cleared from the insoluble material by centrifugation for 15 min at 
12000 x g and 4 °C. For further use protein extracts were stored at -20 °C or  loaded on gels for 
SDS electrophoresis (see 2.3.6).
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 2.3.3 Protein estimation
BCA protein assay kit (Thermo Scientific)
Bradford reagent (Bio-Rad)
Two different methods for protein estimation were used depending on the detergents exerted for 
protein extraction.
I) BCA method, first described by Smith and co-workers (Smith et al., 1985)
This method is divided into two reactions. In a first reaction, the so-called Biuret reac-
tion are Cu2+ ions reduced by negatively charged hydroxyl groups to Cu+. These copper 
ions complex then two bicinchoninic acid molecules, resulting in a violet complex which 
can be photometrically measured.
For the estimation the  BCA protein assay kit (Thermo Scientific) was used. The protein  
extracts were diluted 1:10-1:20 with water and mixed with the kit reagents according to 
the manual. After incubation for 30 min the absorption at 562 nm was measured. The 
protein concentration was finally calculated by means of  a standard curve.
II) Bradford method, first described by (Bradford 1976)
In this method basic and aromatic protein side chains react with Coomassie G-250, which 
is part of  the Bradford reagent (Bio-Rad), shifting its absorption maximum to 595 nm.
For  estimation  protein  extracts  in  different  dilutions  were  mixed  1:5  with  Bradford  
reagent,  incubated  for  5 min  at  RT  and  subsequently  the  absorption  measured  at  
595 nm. The protein concentration was finally calculated by means of  a standard curve.
 2.3.4 Immunoprecipitation (IP)
STEN buffer
50 mM Tris, 150 mM NaCl, 2 mM EDTA, 0.2 % (v/v) NP40 (Sigma-Aldrich), pH 7.6 
STEN-NaCl
50 mM Tris, 500 mM NaCl, 2 mM EDTA, 0.2 % (v/v) NP40 (Sigma-Aldrich), dH2O, pH 7.6 
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Loading dye (5 x)
50 % (v/v) Glycerin, 7.5 % (w/v) SDS, 0.1 M DTT, 0.025 mg/ml Bromphenol blue in stacking gel buffer
Protein A sepharose (Zymed)
Protein G sepharose (Invitrogen)
Specific proteins can be isolated by specific antibodies coupled to protein A (against rabbit IgG) 
or protein G sepharose (against mouse IgG) from cell lysates (see 2.3.2). To prevent unspecific 
binding of  proteins the lysates were pre-cleared with 30 µl uncoupled protein A sepharose beads 
for 1 h at 4 °C on a rotatory shaker. The sepharose was sedimented (2 min, 9300 x g, 4 °C) and 
the supernatant incubated with fresh sepharose beads and generally 1-3 µg of  the specific anti-
body for 2-16 h at 4 °C under constant rotation. Afterwards the beads were sedimented (2 min, 
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9300 x g, 4 °C) and the supernatant discarded. The beads were then washed once with STEN-
NaCl and three times with STEN buffer. Therefore the beads were incubated  for 5 min on a 
rotatory shaker at 4 °C before they were pelleted (2 min, 9300 x g, 4 °C). Finally the beads were 
sucked dry by the use of  a syringe and 0.4 mm needle, taken up in 20 µl of  2 x loading dye and 
boiled 5 min at 95 °C. The samples were then used for SDS electrophoresis (see 2.3.6).
 2.3.5 Co-immunoprecipitation of  DAP12 and TREM2
Brij97 lysis buffer
0.875 % Brij 97, 0.125 % Igepal, 10 mM Tris, 150 mM NaCl
Protein G sepharose (Invitrogen)
Co-immunoprecipitation (co-IP) is a technique to detect protein-protein interactions. For co-IP 
of  DAP12  and  TREM2,  the  Brij97  lysis  buffer  described  by  Voehringer  and  colleagues 
(Voehringer et al., 2004) was used. Cells were lysed, according to 2.3.2 in 800 µl Brij97 lysis buf-
fer. 20 µl of  the cell lysate was taken and the rest pre-cleared as described in 2.3.4. During the 
pre-clearing the protein concentration was estimated by BCA according to  2.3.3. For IP, which 
was accomplished for 16 h, as described in  2.3.4, 1 mg protein per sample was used in equal 
volumes. After the IP the procedure was continued as described in 2.3.4 with the exception that 
the washing steps were performed with Brij97 lysis buffer.
 2.3.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
Stacking gel buffer (4 x) (Upper-Tris)
500 mM Tris, 0.4 % (w/v) SDS, dH2O, pH 6.8
Separation gel buffer (4 x)
1.5 M Tris, 0.4 % (w/v) SDS, dH2O, pH 8.8
SDS loading dye (5 x)
50 % (v/v) Glycerin, 7.5 % (w/v) SDS, 0.1 M DTT, 0.025 mg/ml Bromphenol blue in stacking gel buffer
Ammonium persulfate (APS, Sigma)
10 % (w/v) Ammonium persulfate, dH2O
N,N,N´,N´-Tetramethylethylenediamine (TEMED, Roth)
Running buffer
25 mM Tris, 200 mM Glycine, 0.1 % (w/v) SDS, dH2O
Acrylamide/Bisacrylamide solution
30 % (v/v) Acrylamide/Bisacrylamide in the ratio of  37.5:1
PageRuler™ protein ladder (Fermentas)
PageRuler™ prestained protein ladder (Fermentas)
SeeBlue® prestained standard (Invitrogen)
SeeBlue® Plus prestained standard (Invitrogen)
The separation of  proteins on the basis of  their molecular weight was carried out in 1.5 mm 
thick gels which were casted under the conditions listed in Table 6.
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Table 6: Composition of  the SDS-PAGE gels
Separation gel Stacking gel
12 % 10 % 7 % 4 %
dH2O 7 ml 8.3 ml 10.3 ml 6.2 ml
Acrylamide/Bisacrylamide 8 ml 6.7 ml 4.7 ml 1.3 ml
Lower-Tris 5 ml 5 ml 5 ml -
Upper-Tris - - - 2.5 ml
APS 50 µl 50 µl 50 µl 25 µl
TEMED 50 µl 50 µl 50 µl 25 µl
∑ 20 ml 20 ml 20 ml 10 ml
For the discontinuous electrophoresis a stacking gel is poured atop of  a separation gel. First the 
separation gel, whose percentage was chosen according to needed molecular weight range, was 
prepared and polymerized in a gel caster  with a thin 70 % EtOH film on top. After full polymer-
ization EtOH was carefully removed and the stacking gel casted on top of  the separation gel. For 
pocket  formation  a  comb sealed the  stacking  gel.  5 x  SDS sample  buffer  was added to the 
samples prior to 5 min of  boiling at 95 °C. Approximately 20-30 µg protein was loaded per lane 
with the help of  a Hamilton syringe. The  electrophoresis was performed at 30 mA per gel and a 
maximum voltage of  180 V. As molecular weight standard, PageRuler™ (Fermentas) or PageR-
uler™ prestained were loaded along with the samples. 
Alternatively, precasted 4-12 % Bis-Tris polyacrylamide gels were used (Variogel®, Anamed or 
NuPAGE® gels, Invitrogen). Here, samples were prepared and buffers were used according to 
the manufacturer's instructions. For NuPAGE® gels SeeBlue® or SeeBlue® Plus were loaded as 
protein standard.
 2.3.7 Western immunoblotting (WB)
Blotting buffer
5 mM Tris, 200 mM Glycine, 10 % (v/v) methanol, dH2O
Ponceau solution
3 % (w/v) Ponceau S, 3 % (w/v) trichloroacetic acid, dH2O 
TBS/T
10 mM Tris, 150 mM NaCl, 0.1 % (v/v) Tween20, dH2O, pH 7.5 
PBS/T
PBS, 0.05 % (v/v) Tween20, pH 7.4
TBS/T blocking solution
TBS/T, 4 % (w/v) BSA (Roth) 
PBS/T blocking solution
PBS/T, 4 % (w/v) skimmed milk powder (Roth)
Antibody solutions
TBS-T/PBS-T, specific antibody (for dilution see Table 7)
ECL (1:1 mix of  W1 and W2)
W1: 0.1 M Tris pH 8.5, 0.4 mM cumaric acid, 0.25 mM luminol, dH2O
W2: 0.1 M Tris pH 8.5, 0.018 % H2O2, dH2O
ECL™ advanced Western Blotting Detection Reagent (GE Healthcare)
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The proteins which were separated by their size in the SDS gel were transferred to nitrocellulose 
membranes by WB to allow immuno detection. Before blotting, membranes were equilibrated in 
blotting buffer. The proteins were transferred to the membrane in a blotting chamber at a con-
stant current of  400 mA with a maximum voltage of  120 V for 2 h at 4 °C.
After a completed transfer the efficiency was controlled by Ponceau staining. The membrane was 
incubated in Ponceau solution for  2 min and washed several  times with dH2O till  the bands 
become visible. To prevent unspecific antibody binding the membrane was incubated for 1.5 h in 
4 % skimmed milk in PBS/T. The blocked membranes were incubated in primary antibody solu-
tion (for dilution see Table 7) overnight at 4 °C or for 2 h at RT. In order to remove excess of  
primary antibody the blot was washed four times with PBS/T for 5 min. Afterwards the blot was 
incubated in secondary antibody solution (for dilution see  Table 8) for 1 h at RT followed by 
again washing four times with PBS/T. The secondary antibody is conjugated to HRP, which 
allows a  detection by ECL reagent. The enzyme catalyzes a reaction that leads to chemilumines-
cence. The emitted light was recorded by an ECL Imager (Bio-Rad). Weaker signals were ana-
lyzed with the help of  ECL™ advanced western Blotting Detection Reagent (GE Healthcare). 
The quantification of  specific signals was conducted by the software Quantity One®. 
Table 7: Primary antibodies that were used for western immunoblotting (WB), immunocytochemistry 
(ICC), surface stainings (SurfS), immunoprecipitation (IP) and co-immunoprecipitation (CoIP)
Antibody Target protein WB ICC SurfS IP CoIP Species Company
α-DAP12 DAP12 1:250 1:50 goat Santa Cruz Biotech.
α-GFP GFP 1:10000 2 µg mouse Roche
α-HA HA-tag 1:500 1:400 1:200 4 µg mouse Sigma
α-msGGA1 GGA1 1:500 rabbit Abcam
α-TREM2 TREM2 1:250 1:50 rat R&D System
β-actin Actin 1:2000 mouse Sigma
140 APP 1:500 rabbit Lab AG Walter
2972 GST 1:500 rabbit Lab AG Walter
5313 APP 1:1000 rabbit (Walter et al., 2000)
7520 BACE 1 1:1000 1:300 rabbit (Capell et al., 2000)
7523 BACE 1 1:1000 rabbit (Capell et al., 2000)
AP-1 AP-1 1:300 mouse Sigma
c-myc0 c-myc 1:1000 1:1000 1:500 3 µg 4 µg mouse  (Wahle et al., 2005)
Calnexin H-70 Calnexin 1:1000 mouse Santa Cruz Biotech.
EEA1 EEA1 1:2500 1:300 mouse BD Biosciences
Flag M2 Flag-tag 1:500 1:400 1:200 3 µg 3 µg mouse Sigma
Flotillin Flotillin 1:250 mouse BD Biosciences
Giantin Giantin 1:2500 mouse
TGN46 TGN46 1:250 rabbit Sigma
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Table 8: Secondary antibodies that were used for western immunoblotting (WB), immunocyto-
chemistry (ICC) and surface stainings (SurfS)
Antibody Target protein WB ICC SurfS -conjugated Company
α-gt-HRP goat IgG 1:1000 HRP Sigma
α-ms-HRP mouse IgG 1:50000 HRP Sigma
α-rat-HRP rat IgG 1:50000 HRP Sigma
α-rb-HRP rabbit IgG 1:50000 HRP Sigma
ms-Alexa 350 mouse IgG 1:250 1:100 Alexa 350 Invitrogen
ms-Alexa 488 mouse IgG 1:750 1:400 Alexa 488 Invitrogen
ms-Alexa 594 mouse IgG 1:750 1:400 Alexa 594 Invitrogen
rb-α-ms mouse IgG 1:500 Sigma
rb-Alexa 350 rabbit IgG 1:250 1:100 Alexa 350 Invitrogen
rb-Alexa 488 rabbit IgG 1:750 1:400 Alexa 488 Invitrogen
rb-Alexa 594 rabbit IgG 1:750 1:400 Alexa 594 Invitrogen
 2.3.8 Coomassie staining of  proteins in polyacrylamide gels
Coomassie staining solution
50 % (v/v) Isopropanol, 10 % (v/v) acetic acid, 0.5 % (w/v) Coomassie brilliant-blue R, dH2O
Destaining solution
20 % (v/v) Isopropanol, 10 % (v/v) acetic acid, dH2O
Alternatively to WB the polyacrylamide gels were directly stained with Coomassie. Therefore the 
gels were incubated in Coomassie staining solution for 30 min at RT. To remove excess of  bound 
Coomassie the gels were incubated for another 2-4 h in destaining solution.
 2.3.9 Precipitation of  soluble proteins from cell culture supernatants by trichloroacetic acid  
(TCA)
DOC solution
2 % (w/v) Sodium deoxycholic acid
Trichloroacetic acid (TCA)
100 % (v/v) TCA, dH2O
Acetone
Tris/SDS Buffer
50 mM Tris, 1 % SDS, dH2O
SDS loading dye (5 x)
50 % (v/v) Glycerin, 7.5 % (w/v) SDS, 0.1 M DTT, 0.025 mg/ml bromphenol blue in stacking gel buffer 
1.5 ml supernatant was collected from cultured cells, cleared from cell debris by centrifugation 
(10 min, 300 x g) and 1.3 ml transferred into a new tube. DOC solution was added to a final con-
centration of  0.02 %, mixed vigorously and incubated for 15 min at RT. TCA was added to an 
end concentration of  10 %. After an incubation of  1 h at RT a spin of  10 min at 12000 x g and 
4 °C followed. The supernatant was discarded and the pellet washed twice with ice cold acetone. 
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Therefore, 200 µl of  acetone was added to the pellet,  incubated for 15 min on ice and spun 
10 min at 12000 x g and 4 °C. The washed pellet was air-dried, resuspended in 35 µl Tris/SDS 
buffer and incubated for 10 min at 50 °C. Finally, 10 µl 5 x loading dye were added.
 2.3.10 Expression and isolation of  glutathione S-transferase (GST) fusion proteins
IPTG solution (1000 x)
100 mM IPTG, dH2O
Lysozyme solution (stock)
100 mg/ml, dH2O
Elution buffer
50 mM Tris, 10 mM glutathione (reduced), dH2O, pH 8.0 
Equilibration buffer
50 mM Tris, dH2O, pH 8.0 
GSH-sepharose (Amersham)
Triton solution
25 % Triton X-100, dH2O
400 ml LB medium were inoculated with 10 ml of  an overnight culture and incubated at 250 rpm 
and 37 °C to an OD600 of  0.6-0.8. The expression of  the fusion protein was induced by adding 
IPTG to a final concentration of  0.1 mM. To reach a good amount of  fusion protein the culture 
was incubated for another 5 h under the conditions mentioned above. The cells were pelleted 
(30 min, 3500 x g, 4 °C) and frozen at -20 °C. Later the pellet was resuspended in 20 ml PBS con-
taining 5 mg/ml lysozyme and incubated for 30 min on ice. The cell suspension was then 10 
times sonicated for 30 s with an idle period of  20 s each plus one final sonification step for 
1.5 min. 400 µl Triton solution was added and the mixture incubated 45 min under constant agit-
ation.  The  solution  was  then  cleared  from  the  insoluble  fragments  by  centrifugation 
(30 min, 3500 x g, 4 °C). In the next step the supernatant was diluted 1:5 with PBS, mixed with 
2 ml GSH-sepharose and incubated at 4 °C on an overhead shaker for 2 h. The GSH-beads were 
pelleted (5 min, 2000 x g, 4 °C) and washed in the same way five times with PBS. After the last 
washing step, beads were taken up in 10 ml PBS and carefully packed to a poly-prep chromato-
graphy column (Amersham). In the column the beads were washed two times with equilibration 
buffer. Finally the fusion proteins were eluted from the beads by adding 10 ml elution buffer, 
thereby the eluate was collected in 0.5 ml fractions. Using the Bradford method (see 2.3.3) the 
protein concentration of  each fraction was measured and the purity controlled by Coomassie 
staining (2.3.8) of  an polyacrylamide gel.
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 2.3.11 Biotinylation of  cell surface proteins
Poly-L-lysine solution
100 µg/ml sterile poly-L-lysine in PBS
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Biotin solution
0.5 mg/ml sulfo-NHS-biotin (Pierce) in PBS 
Glycine solution 
20 mM glycine in PBS 
SDS loading dye (5 x)
50 % (v/v) Glycerin, 7.5 % (w/v) SDS, 0.1 M DTT, 0.025 mg/ml bromphenol blue in stacking gel buffer 
STEN lysis buffer
50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) NP40 (Sigma-Aldrich), 1 % (v/v) Triton X-100 (Sigma-Aldrich), dH2O, pH 7.4 
Cells were cultured in poly-L-lysine coated 6 cm dishes to a confluence of  80-90 %. The cells 
were washed twice with ice cold PBS and incubated in 2 ml biotin solution for 30 min on ice 
under constant gentle shaking. The biotin solution was removed and the cells were washed three 
times with glycine solution. The glycine solution of  the last wash was left on cells for 15 min on 
ice. The cells were then washed once with ice cold PBS prior to lysis by addition of  900 µl STEN 
lysis buffer and incubation for 15 min on ice. After the removal of  insoluble cell fractions by 
centrifugation (10 min, 12000 x g, 4 °C), 50 µl of  washed streptavidin-sepharose was added to 
the lysates and the mixture was incubated overnight at 4 °C on a overhead shaker. Finally, the 
streptavidin-sepharose was washed four times for 10 min each with STEN buffer,  pelleted by 
centrifugation (3 min, 600 x g, 4 °C) and boiled in 20 µl of  2 x SDS loading dye. All samples were 
analyzed by SDS-PAGE and WB as described in sections 2.3.6 and 2.3.7.
 2.3.12 Radio-labeling with 32P-orthophosphate
Poly-L-lysine solution
100 µg/ml sterile poly-L-lysine in PBS
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Phosphate free DMEM (Invitrogen) 
Labeling medium
Phosphate free DMEM, 0.5 mCi/dish [32P]-ortho phosphate
RIPA lysis buffer
50 mM Tris, 150 mM NaCl, 0.5 % (w/v) Sodium deoxycholic acid, 0.1 % (w/v) SDS, 1 % (v/v) NP-40, pH 7.4 
Cells were grown to a confluence of  80-90 % on poly-L-lysine coated 6 cm dishes and incubated 
for 1 h in phosphate-free medium. After incubation for 1 h in labeling medium in a CO2 incub-
ator,  cells  were  washed once with PBS and lysed in  1 ml  RIPA lysis  buffer.  The protein  of  
interest was finally isolated by IP as described in  2.3.4. The  [32P]-phosphate incorporation  was 
visualized by autoradiography.
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 2.3.13 TREM2 shedding assay
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
DMEM -/-
PDBu (stock solution)
10 mM PDBu in DMSO
Batimastat (stock solution)
10 mM Batimastat in DMSO
DMSO
Poly-L-lysine solution
100 µg/ml sterile poly-L-lysine in PBS
80-90 % confluent cells were washed once carefully with warm PBS and incubated then for 4 h in 
2 ml  DMEM  -/-  supplemented  with  1 µM  PDBu,  10 µM  Batimastat  or  DMSO  as  control 
respectively. After the incubation supernatants were collected, cleared and used for TCA precipit-
ation (see  2.3.9).  Cells  were  scraped and used for  membrane preparation as  shown in  2.3.1. 
Alternatively  the assay was combined with cell  surface  protein staining as described in  2.1.4. 
Therefore the cells were grown on poly-L-lysine coated CS to the required confluence. CS were 
then placed on parafilm and the cells were incubated with 150 µl DMEM -/- with the chemicals 
mentioned above for 4 h. Finally the parafilm with the CS was transferred on ice prior to follow-
ing the cell surface staining protocol 2.1.4.
 2.3.14 TREM2 activation assay
Poly-L-lysine solution
100 µg/ml sterile poly-L-lysine in PBS
PBS
140 mM NaCl, 10 mM Na2HPO4, 1.75 mM KH2PO4, dH2O, pH 7.4
Phosphate free DMEM (Invitrogen) 
Labeling medium
Phosphate free DMEM, 0.5 mCi/dish [32P]-ortho phosphate
RIPA lysis buffer
50 mM Tris, 150 mM NaCl, 0.5 % (w/v) Sodium deoxycholic acid, 0.1 % (w/v) SDS, 1 % (v/v) NP-40, pH 7.4 
Orthovanadate (stock solution)
20 mM sodium orthovanadate, dH2O
DMEM -/-
In principle the TREM2 activation assay follows the protocol for Radio-labeling with 32P-ortho-
phosphate (2.3.12). Since the natural ligand of  TREM2 is still unknown, the activation of  the 
TREM2/DAP12 system was achieved by cross-linking of  two TREM2 molecules via the N-ter-
minal located myc-tag by an anti-myc antibody. Thus, after 1 h incubation in labeling medium, 
cells were treated with 10 µg/ml anti-myc antibody. To stabilize the phosphorylation of  DAP12 
some dishes (as indicated in fig. 7) were also treated with orthovanadate to a final concentration 
of  200 µM. The cells were then incubated for another hour and it was continued as described in 
2.3.12.
Alternatively the TREM2 activation assay was performed as a non radioactive variant. Therefore, 
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after reaching 80-90 % confluence, the cells were washed once carefully with PBS prior to incub-
ation for 1 h with 2 ml of  DMEM -/- supplemented with 10 µg/ml anti-myc antibody. After-
wards, the supernatants were collected, cleared by centrifugation (300 x g; 10 min) and used for 
TCA precipitation as described in 2.3.9. The cells were used for membrane preparation (2.3.1).
 2.3.15 Aβ-Phagocytosis assay
FAM-Aβ42 
15 µM FAM-Aβ42 (AnaSpec) in PBS, aged 3 days at 37 °C
0.2 % Trypan Blue
125 µg/ml Trypan Blue in PBS, pH 4.4
H33342 solution
50 µg/ml Hoechst 33342 in PBS
DMEM +/+
10000 BV-2 cells/well for 4 h incubation or 5000 cells/well for 18 h incubation were plated into a 
96-well plate. Cells were incubated for 1 h at 37 °C prior to adding the Aβ solution to a final con-
centration of  0.5 µM. After incubation for 4-18 h the medium was aspirated using a multichannel 
pipette. 100 µl Trypan Blue solution was added to each well  and the plate was incubated for 
1 min at RT. The Trypan Blue solution was removed again and the emission at ~535 nm (excita-
tion ~485 nm) was measured in a plate reader. 100 µl H33342 solution was added to each well 
and the plate incubated for 30 min. After complete removal of  the H33342 solution the emission 
at ~465 nm (excitation ~360 nm) was measured in a plate reader.
 2.4 Densitometric quantification of  signals and statistical analysis
Protein signals were quantified by densitometric analysis using Quantity One® software. Statist-
ical analysis of  the experiments were carried out by a two-sided student’s t-test or to compare 
more than two individual groups by an One-way Anova test. If  not indicated differently in the 
figure caption in the result part, the diagrams show the mean values and the corresponding stand-
ard error (SEM) of  three independent experiments. To classify and indicate significant values the 
following P-values were used: P < 5 %, *; P < 1 %, **; P < 0,1 %, ***.
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 3 RESULTS
 3.1 Proteolytic processing of  TREM2 by γ-secretase
 3.1.1 Expression of  PS1 in microglia
While PS1 expression in neurons (Naruse et al., 1998) and astrocytes (Weggen et al., 1998; Diehl-
mann et al., 1999) is well established, less is known about the role of  PS1 in microglia. Only the 
upregulation of  PS1 and nicastrin in microglia after traumatic brain injury was shown, suggesting 
the presence of  a functional γ-secretase complex in these cells (Nadler et al., 2008). In the active 
γ-secretase, PS is present as a heterodimer consisting of  an C-terminal and a N-terminal part (see 
1.1.5.3). To test the expression of  PS1 and PS2 in microglia, the microglial cell line BV-2 as well 
as primary murine microglia were tested. Western immunoblotting demonstrates the expression 
of  PS1 CTF in BV-2 cells, mouse embryonic fibroblasts as well as primary microglia (fig.  7 A). 
The detection of  a CTF and N-terminal fragment (NTF) of  PS1 and PS2 indicates the presence 
of  a functional γ-secretase in these cells (fig. 7 B). Accordingly, the treatment of  BV-2 cells with 
the γ-secretase inhibitor DAPT led to accumulation of  APP CTF (fig.  7 C). As indicated by 
immunofluorescence microscopy, APP CTF accumulates at the cell surface upon treatment of  
BV-2 cells with the γ-secretase inhibitor DAPT (fig. 7 D). All together these experiments indicate 
presence of  functional γ-secretase complex in microglia.
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 3.1.2 γ-secretase dependent processing of  TREM2
Having  established  the  presence  of  active  γ-secretase  in  a  microglia  cell  line  and  primary 
microglia, the next step was to test the proteolytic cleavage of  TREM2. As explained in the intro-
duction γ-secretase processes type I transmembrane proteins after shedding of  their ectodomain. 
If  TREM2 acts as γ-secretase substrate, the pharmacological inhibition of  PS1 should lead to 
accumulation of  a small TREM2 fragment. To prove this, HEK293 cells were transfected with 
cDNA (see table 3, fig.  6) encoding TREM2 (Flag-TREM2-mycHis) and DAP12 (Flag-DAP12-
HA).  TREM2 failed to appear in single transfected HEK293 cells, consistent with findings of  
Bouchon and co-workers, showing that TREM2 expression was partially increased by co-trans-
fection of  DAP12 cDNA (Bouchon et al., 2000). Thus, in all experiments TREM2 was co-ex-
pressed with DAP12. The transfected HEK293 cells were incubated in absence or presence of  
the γ-secretase inhibitor DAPT (Dovey et al., 2001) and subjected to membrane preparation.
Figure 7: Detection of  functional γ-secretase in microglia.
(A) Detection of  PS1 CTF in purified membranes of  BV-2 cells, MEF, MEF deficient for both PS1 and PS2 
(MEF PSdko) and primary microglia by western immunoblotting. Cell membranes were prepared as described 
in methods section (2.3.1) (B) Detection of  NTF and CTF of  both PS variants in purified membranes of  BV-
2 cells by western immunoblotting. (C, D) BV-2 cells were incubated in absence or presence of  1 µM DAPT 
for 24 h. APP CTF was detected by the APP antibody 140 in purified membranes by western immunoblotting 
(C). C99-eGFP was detected in fixed transiently transfected BV-2 cells in immuno stainings (D). Scale bars rep-
resents 10 µM
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In control cells a strong band migrates at 40 kDa and a weak band at 17 kDa. Based on the size 
of  the bands, the upper one represents most likely the full-length variant of  TREM2 (TREM2 
FL) and the lower one might be a CTF of  TREM2. Accordingly, this band increases significantly 
upon incubation with DAPT, while the upper band remains constant. This confirms the lower 
band as TREM2 CTF and indicates that TREM2 represents an immediate γ-secretase substrate 
(see fig. 8). Since DAP12 expression is not altered upon γ-secretase inhibition (data not shown), 
the potential processing of  DAP12 was not analyzed further in this study.
To corroborate the accumulation of  TREM2 CTF through inhibition of  γ-secretase in a genetic 
model,  HEK293 cells  stably  overexpressing  the  wild-type  or  a  dominant  negative  variant  of  
human PS1 were co-transfected with DAP12 and TREM2 (fig. 9 A, C). After membrane prepara-
tion TREM2 was detected by an anti-myc antibody. In PS1 DN HEK293 cells a small C-terminal 
fragment appears, similar to the fragment accumulating after DAPT treatment.
Figure  8: Pharmacological inhibition of  γ-secretase leads to the accumulation of  a TREM2 C-ter-
minal fragment.
(A) HEK293 cells were transiently co-transfected with Flag-DAP12-HA and Flag-TREM2-mycHis (see table 3, 
fig. 6). Cells were incubated for 24 h in the presence or absence of  10 µM DAPT. After membrane preparation 
(2.3.1) and separation by SDS-PAGE (2.3.6), proteins were detected by western immunoblotting (2.3.7) with an 
anti-myc  antibody.  (B) Quantification  of  (A)  by  ECL  imaging,  displayed  as  ratio  of  TREM2  CTF  to 
TREM2 FL 
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To further proof  the γ-secretase dependent TREM2 CTF processing, an artificial TREM2 CTF 
construct (TREM2∆ECD; see fig. 6) was cloned. As usually considered, such a construct encod-
ing a TREM2 variant that consists only of  the C-terminal domain, the tm-domain and 14 aa of  
the ectodomain should be processed directly, because γ-secretase processes C-terminal stubs of  
proteins with a short (~10-15 aa) ectodomain (Hemming et al., 2008). Thus, HEK293 cells were 
transfected with TREM2∆ECD and DAP12 (fig.  9 B, D). Importantly, TREM2∆ECD strongly 
accumulates in PS1 DN cells comparable to the CTF derived from the full-length TREM2.
Fig.  8 and  9 show that γ-secretase inhibition either by a pharmacological or genetic approach 
leads to the accumulation of  TREM2 CTFs. Next, it was investigated whether PS1 FAD mutants 
(De Strooper 2007; Wolfe 2007) also affect the proteolytic processing of  TREM2. To test this, 
HEK293 cells stably overexpressing two of  the most severe FAD mutants were co-transfected 
with TREM2 and DAP12 (fig. 10). The strongest TREM2 CTF accumulation (80 % more com-
pared to WT) is detected in the PS1 DN cells. More importantly, there is also a significant accu-
mulation (30 % more compared to WT) of  TREM2 CTFs in cells expressing the PS1 L166P 
FAD mutation. Cells expressing PS1 ∆Ex9 also show a trend towards TREM2 CTF accumulation 
(fig. 10).
Figure 9: TREM2 is proteolytically processed by γ-secretase.
(A, B) HEK293 cells stably expressing PS1 WT or DN variants were transfected with Flag-TREM2-mycHis 
and Flag-TREM2∆ECD-mycHis respectively in combination with Flag-DAP12-HA. After membrane prepara-
tion (2.3.1) and SDS-PAGE (2.3.6), TREM2 was detected by western immunoblotting (2.3.7) with an anti-myc 
antibody. (B, C) Quantification of  (A, B) two independent experiments by ECL imaging, displayed as ratio of  
TREM2 CTF to TREM2 FL and TREM2∆ECD levels respectively.
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Taken  together,  it  was  shown that  the  inhibition  of  γ-secretase  either  by  a  pharmacological 
approach or in cells expressing mutant variants of  PS1 results in accumulation of  TREM2 CTFs. 
Furthermore, the artificial construct TREM2∆ECD which is similar to a direct γ-secretase con-
struct accumulates after genetic PS1 inhibition. Thus, these data demonstrate that TREM2 is a γ-
secretase substrate.
The next step was to find out more about the localization of  this cleavage process and whether 
TREM2 is also subjected to ectodomain shedding.
 3.2 Characterization of  γ-secretase dependent processing and 
localization of  TREM2
 3.2.1 Cleavage of  TREM2 occurs at the cell surface
The γ-secretase substrates APP CTF and Notch are cleaved either on the plasma membrane or in 
endosomal/lysosomal  compartments  (Matsuda  et  al.,  2009;  Sorensen & Conner 2010).  Since 
TREM2 could interact with cell surface molecules on apoptotic cells (Hsieh et al., 2009) or bac-
teria (Daws et al., 2003), the localization of  TREM2 in cells with or without inhibited γ-secretase 
was analyzed by immunocytochemistry.
HeLa cells were transfected with TREM2 and incubated for 24 h in the presence and absence of  
Figure 10: FAD mutations of  PS1 lead to accumulation of  TREM2 CTFs.
(A) HEK293 cells stably overexpressing the indicated PS1 mutants or PS1 WT were transiently co-transfected 
with Flag-TREM2-mycHis and Flag-DAP12-HA. After membrane preparation (2.3.1) and separation by SDS-
PAGE (2.3.6), the TREM2 full-length (FL) and TREM2 CTF was detected by western immunoblotting (2.3.7) 
with an anti-myc antibody. β-Actin was detected as loading control.  (B) Quantification of  (A) was done by 
ECL imaging, ratio of  TREM2 CTF to TREM2 FL is displayed. 
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DAPT respectively (fig.  11). Since staining with an anti-flag antibody was not possible, the cells 
were stained with an anti-myc antibody.
While TREM2 FL detected via the C-terminal myc-tag is mainly localized in vesicular compart-
ments  in  untreated cells,  the  DAPT treatment  leads  to  strong  localization  at  the  membrane 
(fig. 11). The increased signal at the plasma membrane could either be attributed to TREM2 FL 
which is transported to the cell surface in response to the DAPT treatment or to accumulation of  
TREM2 CTF.
To specifically test whether TREM2 CTF accumulates at the cell surface of  transfected COS7 
cells, TREM2∆ECD was stained at the surface of  living cells as described in 2.1.4. In  untreated 
COS7 cells  TREM2∆ECD shows a dotted pattern,  which is  typical  for cell  surface stainings 
(fig. 12). In contrast to this, upon DAPT treatment the TREM2∆ECD positive structures on the 
cell surface increase strongly in size (fig. 12).
Figure 11: Inhibition of  γ-secretase changes the localization of  TREM2.
HeLa cells were transiently transfected with a Flag-DAP12-HA and Flag-TREM2-mycHis and incubated with 
or without 10 µM DAPT for 24 h. Cells were fixed with PFA and permeabilized with Triton X-100 followed by 
staining with anti-myc antibodies and a secondary Alexa 594-coupled antibody to detect TREM2. For a detailed 
protocol see 2.1.4. Scale bar represents 20 µM. Two representative images of  each group are shown.
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Next, the accumulation of  TREM2 CTF was quantified by cell surface-biotinylation (fig. 13). As 
shown before (fig. 8), TREM2 CTFs accumulate in DAPT treated cells, while TREM2 FL is not 
changed (fig. 13 A, C). Notably, the increasing amount of  biotin-labeled TREM2 CTFs demon-
strate accumulation at the cell surface (fig.  13 B, D), thereby confirming the observed surface 
staining of  the artificial TREM2 CTF upon γ-secretase inhibition (fig.  12). Since biotin-labeled 
TREM2 FL doesn't increase (fig.  13 B) the enhanced reactivity at the cell surface detected by 
immunocytochemistry (fig. 11) cannot be caused by TREM2 FL accumulation.
TREM2 signaling is dependent on the engagement of  the receptor with the adapter DAP12 via a 
charged aspartate in the tm-region of  DAP12 (see 1.5.2 and 1.6). To test whether this interaction 
can regulate the cleavage of  TREM2 an interaction mutant of  DAP12 was cloned by substituting 
the aspartate at position 52 against alanine (DAP12 D52A, see fig. 6) (Hamerman et al., 2006).
The TREM2 CTF accumulation at the cell surface relating to DAP12 interaction was checked by 
a second biotinylation experiment with HEK293 cells expressing TREM2 and DAP12 D52A (fig. 
14)
Figure 12: Inhibition of  γ-secretase alters the distribution of  TREM2 at the cell surface.
COS7 cells transiently transfected with Flag-TREM2∆ECD-mycHis and DAP12-HA were incubated for 24 h 
with or without 10 µM DAPT and stained on ice against the Flag-tag of  TREM2∆ECD by an anti-Flag anti-
body and an Alexa 594-coupled secondary antibody. For quantification 10 different areas (75 px x 75 px, white 
square) of  five different cells of  each group were randomly chosen and the areas of  the Flag-positive struc-
tures were measured. Scale bar represents 20 µM. One representative image of  each group is shown.
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Both in lysates (fig.  14 A, C) and at the plasma membrane (fig.  14 B, D) TREM2 FL is not 
changed upon DAPT treatment. However, CTFs in DAPT treated cells accumulate significantly 
in  lysates as well as at the plasma membrane, indicating that TREM2 CTF cleavage occurs inde-
pendently of  interaction with DAP12.
The interaction with DAP12 was demonstrated to regulate the surface expression of  TREM2 FL 
(Bouchon et al., 2000). The only known interaction site so far is the charged amino residue in the 
transmembrane region of  both proteins.  Although the interaction mutant  DAP12 D52A was 
expressed together with TREM2 in the previous experiment, TREM2 FL is detectable at the 
plasma membrane. This finding suggests that transport of  TREM2 to the cell surface can occur 
independently of  DAP12. Alternatively, there might be other unknown motifs involved in the 
interaction between TREM2 and DAP12 or other signaling related proteins regulate the cell-sur-
face expression of  TREM2.
Figure 13: TREM2 CTFs accumulate at the cell surface after γ-secretase inhibition.
HEK293 cells were transfected with Flag-TREM2-mycHis in combination with Flag-DAP12-HA and incub-
ated for 24 h in absence or presence of  10 µM DAPT. Surface proteins were biotinylated wit sulfo-NHS-biotin 
for 30 min followed by lysis and streptavidin-IP (2.3.11). Aliquots of  cell lysates (A) and streptavidin-IPs (B) 
were separated by SDS-PAGE. TREM2 was detected by western immunoblotting with an anti-myc antibody. 
(C, D) Quantification of  (A, B) by ECL imaging, ratio of  TREM2 CTF and TREM2 FL is displayed.
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 3.2.2 γ-secretase mediated processing in response to the activation of  TREM2.
There are several ways to inactivate receptors upon ligand binding and activation. The ligand-re-
ceptor complexes could be taken up by endocytosis and be further degraded. Alternatively, the 
complexes could be cleaved directly  at the membrane.  It is known that ligand binding could 
induce the shedding of  the ECD of  Notch, allowing subsequent γ-secretase cleavage which leads 
to an increase in Notch ICD, a small fragment transported to the nucleus where it has gene regu-
latory function (Schroeder et al., 1998; Mumm et al., 2000).  The induced receptor cleavage is also 
known for G-protein coupled receptors like the V2 vasopressin receptor  (Kojro & Fahrenholz 
1995), thereby downregulating the receptors.
However, nothing is known about the downregulation of  the TREM2/DAP12 signaling. To test 
whether  TREM2  activation  alters  γ-secretase  processing  HEK293  PS1  WT  and  DN  cells, 
expressing myc-TREM2-GFP/DAP12-HA were subjected to a non-radioactive TREM2 activa-
tion assay as described in  2.3.14 (fig.  15).  Since no ligand of  TREM2 is known, myc-tagged 
TREM2 was activated by ligation with an anti-myc antibody. 
Figure 14: Interaction with DAP12 is not prerequisite for γ-secretase mediated TREM2 cleavage.
HEK293 expressing Flag-TREM2-mycHis in combination with Flag-DAP12 D52A-HA were incubated for 
24 h in absence and presence of  10 µM DAPT. After biotinylation with sulfo-NHS-biotin, lysis and streptavid-
in-IP (2.3.11) aliquots of  cell lysates (A) and streptavidin-IPs (B) were separated by SDS-PAGE. TREM2 was 
detected by western immunoblotting with an anti-myc antibody. (C, D) Quantification of  (A, B) was done by 
ECL imaging.
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Upon activation, levels of  TREM2 FL changes neither in PS1 WT nor in PS1 DN cells. How-
ever, as previously shown, TREM2 CTF accumulates in HEK293 PS1 DN cells (fig. 15). Notably, 
after TREM2 activation by antibody cross-linking a slight increase in TREM2 CTFs is observed 
in HEK293 PS1 DN as compared to PS1 WT cells, but this difference doesn't reach significance.
Taken together, all these data indicate that proteolytic processing of  TREM2 CTFs occurs at the 
plasma membrane dependent on the activation state of  TREM2. 
 3.2.3 TREM2 ICD is not translocated to the nucleus
γ-secretase cleavage of  substrate CTFs results in release of  ICDs to the cytosol (see 1.1.4). The 
ICD of  Notch is known to translocate to the nucleus upon generation, regulating expression of  
various target genes. The ICDs of  several other γ-secretase substrates are very unstable due to 
efficient proteolytic degradation. Since detection of  TREM2 ICD (TICD) after overexpression 
of  TREM2 FL by western immunoblotting and immunostainings was not possible (not shown), 
an artificial TICD construct was generated starting one amino acid behind the putative tm-do-
main (see table  3, fig.  6). To test the localization of  this fragment, HeLa cells were transiently 
transfected and  subjected  to  immunofluorescence  stainings  (fig.  16).  The  transfected  TICDs 
reveal no nuclear staining, but a vesicular stain, distributed over the whole cell. 
Figure 15: γ-secretase cleavage in response to activation of  TREM2.
(A) HEK293 cells stably expressing PS1 WT and DN were transiently transfected with myc-TREM2-GFP. 
24 h after transfection medium was changed against DMEM -/- or DMEM -/- supplemented with 10 µg/ml 
anti-myc antibody and cells were incubated for 1 h (for detailed protocol see 2.3.14). Membrane proteins were 
isolated as described in 2.3.1. After SDS-PAGE TREM2 FL & CTF were detected by western immunoblotting 
with an anti-GFP antibody.  (B) Quantification of  TREM2 FL and CTF by ECL imaging, normalized to β-
actin which served as loading control. Ratio of  TREM2 CTF/FL is shown.
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 3.2.4 TREM2 ectodomain shedding by an protease of  the ADAM or MMP family.
γ-Secretase  processing  requires  prior  cleavage  of  large  ectodomains  (Hemming  et  al.,  2008) 
(see 1.1.5.3).
The accumulation of  TREM2 CTFs upon γ-secretase inhibition (see chapters  3.1.2 and  3.2.1) 
strongly indicates that TREM2 can undergo ectodomain shedding (see fig. 8, 9 A, 13, 14). Thus, 
it  was first  checked  whether  an ectodomain  of  TREM2 is  detectable  in  the  supernatant  of  
TREM2 expressing  cells.  HEK293  PS1  WT and  PS1  DN cells  were  transfected  with  myc-
TREM2-GFP construct and used for a shedding assay (see 2.3.13). Since it is known that ligand 
binding could induce ectodomain cleavage (Bozkulak & Weinmaster 2009; Rahimi et al., 2009), 
the production of  a ECD was analyzed with or without TREM2 activation (see 2.3.14). 
Importantly, two TREM2 ECD bands are detected in the supernatants (fig. 17) of  both PS1 WT 
and PS1 DN cells, indicating that the generation of  this derivative is γ-secretase independent. The 
two bands might represent differently glycosylated forms of  TREM2, because two potential sites 
for N-glycosylation (aa 20 and aa 79) are present in the ectodomain of  TREM2 (UniProtKB, 
Q99NH8). 
While levels of  TREM2 FL and ECD decrease significantly in HEK293 PS1 WT cells after liga-
tion of  myc-tagged TREM2 with an anti-myc antibody, TREM2 ECD is unaffected in HEK293 
PS1 DN after ligation of  TREM2 (fig. 17 B). Although, TREM2 FL levels decrease significantly 
in HEK293 PS1 DN as compared to HEK293 PS1 WT cells,  the levels of  TREM2 FL are 
unchanged with or without activation (fig. 17 C).
Notably, the detection of  the ECD band, demonstrates existence of  a shedding process and rules 
out that CTFs are generated by ECD degradation processes.
Figure 16: TREM2 ICD is not translocated to the nucleus
HeLa  cells  were  transiently  transfected  with  TREM2  ICD-mycHis.  After  fixation  and  permeabilization, 
TREM2 ICD was stained with an anti-myc antibody and an Alexa 594-coupled secondary antibody. Three rep-
resentative cells are shown. Scale bar represents 20 µM.
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Proteases of  the MMP (matrix metallo protease) family or the ADAM (A disintegrin and metallo-
protease) are known to act as sheddases (Edwards et al., 2008). Other proteases which can act as 
sheddases are BACE-1 and BACE-2. So far, members of  the ADAM protease and MMP family 
as well as BACE-2 are known to be expressed in microglia (Satoh & Kuroda 2000; Dominguez et 
al., 2005; Woo et al., 2008; Pul et al., 2009). In contrast BACE-1 is expressed mainly in neurons 
whereas there is minor expression in glia cells  (Sinha et al., 1999; Vassar et al., 1999), so the 
expression of  BACE-1 was first revealed in microglia derived from mouse embryonic stem cells 
(ESdM) (Napoli et al., 2009; Beutner et al., 2010), obtained from the group of  Prof. Neumann 
(Institute of  Reconstructive Neurobiology, Bonn). Two bands of  60-70 kDa are detected by IP 
(fig. 18 A), which are also present in HEK293 cells. These two variants might represent immature 
and mature form of  BACE-1 (Vassar et al., 1999), showing that BACE-1 is present in microglia 
and can probably serve as sheddase for  TREM2 in these  cells.  In  order  to  study  a  putative 
Figure 17: TREM2 ECD can be detected in supernatant of  TREM2 overexpressing cells.
(A) HEK293 PS1 WT and DN cells were transiently transfected with myc-TREM2-GFP and DAP12-HA. 24 h 
after transfection medium was changed against DMEM -/- or DMEM -/- supplemented with 10 µg/ml anti-
myc antibody and cells were incubated for 1 h. Membrane proteins were isolated (2.3.1) and TREM2 ECD was 
precipitated with TCA of  cleared cell culture supernatant according to  2.3.9. All proteins were separated by 
SDS-PAGE (2.3.6). TREM2 FL and ECD were detected by western immunoblotting with an anti-myc anti-
body. β-actin served as loading control.  The bands indicated with * and ** might represent differently glyc-
osylated forms of  TREM2. (B, C) Quantification of  the detected bands by ECL imaging. Ratio of  TREM2 
ECD/FL and TREM2 FL levels are shown.
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TREM2 shedding mechanism, HEK293 cells were transfected with DAP12 and TREM2 together 
with or without one of  the putative sheddases BACE-1 (fig.  18), ADAM-10 and BACE-2 (fig. 
19). Since the ECD could not be detected in this experiment, the effect of  the three putative 
sheddases is only expressed as changes in the FL and CTF band of  TREM2.
Overexpression  of  BACE-1  leads  to  a  strong  decrease  of  TREM2 FL  but  no  increase  of  
TREM2 CTF, nonetheless resulting in an increased ratio of  TREM2 CTF/FL (fig. 18 B, C). 
Interestingly, while the overexpression of  BACE-1 alone results in a strong increase of  sAPP, co-
expression with TREM2 diminishes this effect (fig. 18 B). One explanation for this effect might 
be a substrate competition for BACE-1. 
Comparable effects are observed after overexpression of  the putative sheddases ADAM-10 and 
BACE-2. Since CTF levels are unchanged, the alteration of  the TREM2 CTF/TREM2 FL ratio 
results mainly from the decreased TREM2 FL levels (fig.  18, 19). An explanation might be the 
Figure 18: BACE-1 overexpression increases the ratio of  TREM2 CTF/TREM2 FL.
(A) Detection of  endogenous BACE-1 in ESdMs and HEK293 cells. BACE-1 was detected after IP (2.3.4) and 
SDS separation (2.3.6) in western immunoblotting (2.3.7) by the polyclonal antibody 7520. (B) HEK293 cells 
were  transfected  with  Flag-TREM2-mycHis  and  Flag-DAP12-HA  in  combination  with  BACE-1  or  with 
BACE-1 alone. Membrane proteins (Membrane fraction) were isolated as described in 2.3.1. Cell culture super-
natants were cleared and extracellular proteins (Sup.) precipitated with TCA (2.3.9). After separation by SDS-
PAGE (2.3.6), indicated proteins were detected by western immunoblotting (2.3.7). TREM2 FL and CTF were 
detected with an anti-myc antibody, BACE with the polyclonal antibody 7520, APP and sAPP with the poly-
clonal antibodies 140 and 5313 respectively. (C) TREM2 FL and CTF bands of  two independent experiments 
were quantified by ECL imaging and shown as ratio of  TREM2 CTF/FL.
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alteration of  protein expression due to triple transfection. This would also explain the decreased 
levels of  all sheddases, when they were expressed in combination of  DAP12 and TREM2.
To further characterize the identity of  the TREM2 sheddase, experiments were carried out using 
pharmacological inhibitors or activators of  ADAM and MMPs protease families.
Batimastat  is  a  well  known  metalloprotease  inhibitor  with  broad  specificity  for  MMPs  and 
ADAMs in the used concentration. The phorbol ester PDBu is an activator of  protein kinase C 
(PKC) which was shown to stimulate shedding of  cell surface proteins (Horuk & Gross 1990). 
Pervanadate, a potent tyrosine phosphatase inhibitor was also shown to activate sheddases of  the 
ADAM and the MMP families (Codony-Servat et al., 1999; Gutwein et al., 2003).
TREM2/DAP12 transfected HEK293 cells were incubated with these substances to investigate 
the involvement of  ADAMs in the shedding of  TREM2.
The  treatment  with  the  metalloprotease  inhibitor  Batimastat  results  in  an  increase  of  the 
TREM2 FL band just as a decrease of  the TREM2 CTF band (fig. 20 A, B), while TREM2 ECD 
levels are slightly  elevated (fig.  20 A, C).  This leads to the assumption that proteases  of  the 
Figure 19: ADAM-10 overexpression increases ratio of  TREM2 CTF/TREM2 FL.
(A)  HEK293 cells  were  transfected with  Flag-TREM2-mycHis  and Flag-DAP12-HA in  combination with 
ADAM-10 or BACE-2. To control the effect of  triple transfection additionally untransfected HEK293 cells 
were transfected with one of  the proteases alone. Membrane proteins (Membrane fraction) were isolated as 
described in  2.3.1 whereas extracellular proteins (Sup.) were precipitated with TCA from cleared cell culture 
supernatants  (2.3.9).  After  separation by  SDS-PAGE (2.3.6),  indicated  proteins  were  detected  by  western 
immunoblotting (2.3.7). TREM2 FL and CTF were detected with an anti-myc antibody, BACE-2 with the poly-
clonal antibody 7524 and sAPP with the polyclonal antibody 5313. (B) TREM2 FL and CTF bands were quan-
tified by ECL imaging, ratio of  TREM2 CTF to FL is shown.
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ADAM or MMP families participate in shedding of  the TREM2 ectodomain. Besides inhibition 
of  the putative TREM2 sheddase, Batimastat might also inhibit subsequent degradation of  the 
ECD, thereby stabilizing this fragment in supernatants. This might contribute to the altered levels 
of  TREM2 ECD. 
Pervanadate  which  is  an  1:1  mixture  of  vanadate  and  H2O2 was  shown to activate  MMP-1 
(Codony-Servat et al.,  1999) and ADAM-10  (Gutwein et al.,  2003). The incubation with per-
vanadate and the control  substances vanadate and H2O2,  has no effect on TREM2 shedding 
Figure 20: Pharmacological modulation of  TREM2 shedding.
(A) Membrane proteins were isolated from HEK293 cells (2.3.1) transfected with Flag-DAP12-HA and Flag-
TREM2-mycHis treated with Batimastat (10 µM), PDBu (1 µM), pervanadate (100 µM), vanadate (100 µM) or 
H2O2 (100 µM) for 4 h respectively. Soluble proteins were precipitated out of  cleared cell culture supernatants 
(2.3.9). Both membrane proteins (Membrane fraction) and precipitated proteins (Sup.) were separated on SDS-
gels (2.3.6). After western immunoblotting, TREM2 FL and CTF were detected by an anti-myc antibody, APP 
by the polyclonal antibody 140 and sAPP by 5313. (B, C, D) Quantification of  two independent experiments 
by ECL imaging. Ratios of  TREM2 CTF to FL, TREM2 ECD to FL and sAPP levels are shown.
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(fig. 20 A, B), suggesting that MMP-1 and ADAM-10 might not represent major TREM2 shed-
dases. However, TREM2 ECD levels are slightly increased with pervanadate (fig. 20 A, C). Para-
doxically, the well established shedding activators PDBu and pervanadate don't alter the shedding 
of  TREM2, demonstrated by the unaltered TREM2 CTF/FL ratio and ECD levels. However, as 
expected sAPP levels increase upon treatment with PDBu and pervanadate, confirming the activ-
ity of  both modulators. 
In fig.  20 the effect of  different shedding modulators is addressed, but the levels of  TREM2 
ECD don't match to the TREM2 CTF/FL ratio. To further establish an effect of  these modulat-
ors  on  the  TREM2 FL-expression  at  the  cell  surface,  myc-TREM2-GFP was analyzed  by  a 
microscopic  approach.  In  the  used  construct,  the  myc-tag  allows  the  specific  detection  of  
TREM2 FL at the plasma membrane, whereas the GFP-tag allows estimation of  the total expres-
sion. 
COS7 cells transfected with DAP12-HA and myc-TREM2-GFP were incubated with the indic-
ated substances and myc-tagged extracellular part of  TREM2 was stained at the surface of  living 
cells as described in 2.1.4.
In untreated and DMSO treated cells, only minor amounts of  TREM2 are detected at the cell 
surface, suggesting that TREM2 undergoes efficient constitutive shedding in COS7 cells (fig. 21 
G, H, I). The amount of  surface localized TREM2 FL is significantly decreased when cells were 
incubated for one hour with PDBu (fig.  21 D, E, F). In contrast, the treatment with the broad 
sheddase inhibitor Batimastat results in a markedly increase of  myc-positive dots on the cell sur-
face  (fig.  21 A,  B,  C).  The quantification of  10 cells  with  five  randomly  chosen squares  of  
75 x 75 px each, yield an averaged number of  25 dots for Batimastat. Both untreated and DMSO 
treated cells show less than 10 dots per square. 
Interestingly, the GFP staining which represents the C-terminal part of  TREM2 is similar under 
all tested conditions. This suggests that large fractions of  TREM2 are localized in intracellular 
compartments which would be consistent to the localization pattern of  TREM2 observed in 
microglia (Sessa et al., 2004; Prada et al., 2006). However, it is also possible that TREM2 exists 
predominantly in a variant lacking the lumenal domain on the cell surface (fig. 21 B, E, H, K).
Taken together, these experiments clearly show that TREM2 undergoes shedding. However, the 
nature of  the involved protease could not be clarified completely. The sensitivity to PDBu and 
Batimastat substantiate the suspicion that ADAMs, most likely ADAM-17 are involved in the 
shedding process, but involvement of  other proteases like BACE-1 or MMPs could not be ruled 
out. 
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Figure 21: Treatment with Batimastat increases the TREM2 surface expression.
(A-L) COS7 cells were transfected with myc-TREM2-GFP and DAP12-HA. Cells were then treated with the 
indicated substances,  (A-C) Batimastat (10 µM), (D-F) PDBu (1 µM) and (G-I) DMSO as control. After 1 h 
incubation the surface localization of  TREM2 was visualized by an surface staining using an anti-myc antibody 
in combination with the Alexa 594-coupled secondary antibody. (M) Numbers of  the cell surface located myc-
positive dots were counted in 5 randomly chosen sectors of  75 x 75 px of  10 cells each. Scale bars represent 20 
µm.
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 3.3 Role of  TREM2 processing in the interaction with DAP12
 3.3.1 Inhibition of  γ-secretase facilitates co-localization of  TREM2 and DAP12 at the cell  
surface.
After showing that TREM2 is cleaved by a sheddase generating a C-terminal fragment which is 
subsequently  cleaved  by  the  γ-secretase  (see  chapters  3.1 and  3.2),  it  was  next  investigated 
whether processing alters the interaction of  TREM2 with its co-repressor DAP12. 
To test  this,  COS7 cells  transfected with  Flag-TREM2∆ECD-mycHis  and DAP12-HA,  were 
treated with or without DAPT and subjected to surface immunostaining (see 2.1.4). To visualize a 
putative co-localization of  DAP12 with the accumulated TREM2∆ECD, cells were fixed and per-
meabilized after surface staining and stained for total DAP12 expression via the C-terminal HA-
tag of  the DAP12 construct.
The total DAP12 stain shows a diffuse but in some areas dotted pattern (fig. 22 B, E ). The co-
localization between TREM2∆ECD and DAP12 is very limited (fig. 22 C, F ). Upon γ-secretase 
inhibition with DAPT, the surface staining of  TREM2 increases and changes from a punctuated 
to a more elongated, spiry shape, distributed over the whole cell. Interestingly, DAP12 shows 
very similar changes in the localization (fig. 22 H, K ), reaching complete co-localization (fig. 22 I, 
L ), indicating that TREM2 CTF interacts with DAP12 at the cell surface and affect its localiza-
tion upon γ-secretase inhibition.
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 3.3.2 Processing of  TREM2 alters the interaction with DAP12
To further analyze whether the interaction of  TREM2 and DAP12 is dependent on γ-secretase 
activity,  co-immunoprecipitation  experiments  were  performed  in  transfected  HEK293  cells 
treated with or without DAPT as well as in HEK293 PS1 WT and DN (fig. 23 C). 
As shown in fig. 23 A and C, complexes of  TREM2 and DAP12 can be isolated out of  cell lys-
Figure 22: Co-localization of  TREM2∆ECD and DAP12 upon cell treatment with DAPT.
COS7 transiently transfected with Flag-TREM2∆ECD-mycHis and DAP12-HA were incubated 24 h with or 
without 10 µM DAPT and stained on ice against the Flag-tag of  TREM2∆ECD by an anti-Flag antibody and 
the secondary antibody Alexa 594. After the specific cell surface staining the cells were fixed in 4 % PFA, 
permeabilized with Triton X-100 and stained against DAP12 with an anti-HA antibody and the secondary 
antibody Alexa 488. 
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ates.  Interestingly,  the  interaction  of  TREM2  FL  with  DAP12  markedly  decreases  in  cells 
expressing the dominant negative form of  presenilin (fig.  23 A, B), indicating that loss of  γ-
secretase function impairs interaction of  TREM2 FL with DAP12. Decreased complex forma-
tion is also detected upon pharmacological γ-secretase inhibition with DAPT (fig. 23 C, D). How-
ever, these findings are completely contrary to trapping of  DAP12 at the cell surface after DAPT 
treatment as shown in fig. 22. 
To control the identity of  the precipitated proteins, in one lane of  each blot the protein was pre-
cipitated with the antibody later used for detection (lane labeled with IP control). Precipitation 
out of  single transfected HEK293 cells results in a clean lane, evidencing the specificity  of  the 
performed co-IPs. 
One explanation for the contrary findings might base on the experimental conditions. The main 
pool of  TREM2 is located in the Golgi and in exocytic vesicles and only a minor part is located 
at the membrane. While the surface staining experiment in fig.  22 visualizes TREM2/DAP12 
interaction at the cell surface, the Co-IP strategy addresses TREM2/DAP12 interaction in the 
whole cell. Thus, if  binding of  DAP12 by TREM2 CTF occurs only at the cell surface, precipita-
tion of  the intracellular TREM2 would mask the cell surface effect. Moreover, the decrease of  
TREM2/DAP12 interaction upon γ-secretase inhibition might be explained by massive transloca-
tion of  DAP12 from intracellular pools to the cell membrane.
 3.3.3 Inhibition of  γ-secretase suppresses phosphorylation of  DAP12 upon TREM2 
activation
Ligand-dependent  activation of  TREM2 causes  the  interaction  with  the  co-receptor  DAP12 
which subsequently induces phosphorylation of  DAP12 (Takaki et al., 2006; Lanier 2009), trig-
gering activation of  microglia or inducing phagocytosis (Neumann & Takahashi 2007; Takahashi 
et al., 2007). Therefore, a potential involvement of  γ-secretase in the regulation of  phosphoryla-
tion of  DAP12 was analyzed.
Cells co-expressing TREM2 and DAP12 were labeled with  32P-orthophosphate in absence or 
presence of  DAPT to inhibit γ-secretase. The two weak bands in the first lane of  fig. 24. repres-
ent the phosphate incorporation of  DAP12 one hour after activation of  TREM2. As compared 
to control cells, presence of  orthovanadate strongly increases phosphorylation of  DAP12, indic-
ating that DAP12 is efficiently dephosphorylated by phospho-tyrosine phosphatases. This in fact 
also indicates that the phosphorylation of  DAP12 takes place at tyrosine residues. Two tyrosine 
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residues in DAP12 are located within the ITAM domain, which have been shown to be important 
for DAP12 signaling (Lanier et al., 1998; McVicar et al., 1998).
Notably, DAPT treatment selectively decreases the phosphorylation of  the lower migrating vari-
ant of  DAP12 (fig. 24). The nature of  these two bands is unclear but they might represent differ-
entially phosphorylated forms of  DAP12. Thus, inhibition of  γ-secretase might selectively affect 
the phosphorylation of  a single Tyr residue of  DAP12. As a control, a DAP12 mutant in which 
both tyrosines (Y92, Y103) of  the ITAM domain were mutated against phenylalanine  (Hamer-
Figure 23: Inhibition of  γ-secretase alters the association of  TREM2 and DAP12.
(A) HEK293 PS1 WT and DN cells  were transiently  co-transfected with  Flag-TREM2-mycHis and Flag-
DAP12-HA.  Cell  lysates  were  precipitated  with  an  anti-myc  monoclonal  antibody  (2.3.5).  Co-precipitated 
DAP12 was detected by western immunoblotting by an anti-HA antibody. Specificity of  the co-IPs is indicated 
by the lack of  signals when DAP12 alone  was transfected (lane labeled with DAP12). Last lane (labeled with IP 
control) represents a control in which the protein was detected with the antibody used for precipitation.  (B) 
HEK293 cells  were co-transfected with TREM2-mycHis and DAP12-HA and incubated for 24 h with or 
without 10 µM DAPT. TREM2 was immunoprecipitated (2.3.5) with an anti-myc antibody and separated by 
SDS-PAGE (2.3.6). DAP12 was visualized with an anti-HA antibody. Lane 5 (labeled with IP Ctrl) represents a 
control in which DAP12 was immunoprecipitated and detected with an anti-HA antibody. To test the spe-
cificity of  the co-IP two lanes represent  control cells  in which only DAP12 was transfected (labeled with 
DAP12). The last lane (labeled with D52A/TREM2) represents a control were the interaction site mutant of  
DAP12, in which the charged aspartate is mutated against alanine was transfected. (C, D) The DAP12 bands 
of  two independent experiments (A, B) were quantified by ECL imaging. 
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man et al., 2005) was transfected. This variant is not phosphorylated. Western immunoblotting 
(fig. 24, lower panel, WB) indicates that equal amounts of  DAP12 are precipitated. 
 3.4 Inhibition of  γ-secretase inhibition in microglia.
The data of  fig. 23 and 24 indicate that the inhibition of  TREM2 cleavage influences the interac-
tion  of  TREM2 with  DAP12.  Interestingly,  the  subsequent  phosphorylation  of  the  DAP12 
ITAM domain is inhibited and might interfere with downstream signaling. These processes might 
finally alter microglia specific processes like phagocytosis, cell-adhesion or migration.
 3.4.1 Inhibition of  γ-secretase in PS1 FAD mutants decrease phagocytosis of  Aβ
γ-secretase is known to play an important role in endocytosis of  lipoprotein receptors in mouse 
embryonic fibroblasts (Tamboli et al., 2008). Since phagocytosis is a special form of  endocytosis 
it could be assumed that γ-secretase is also involved in phagocytosis processes. However, besides 
Figure 24: Inhibition of  γ-secretase impairs the phosphorylation of  DAP12.
HEK293 cells were transiently transfected with myc-TREM2 in combination with DAP12-HA and incubated 
for 24 h in presence or absence of  10 µM DAPT. As control, a mutant where both phosphorylation sites in the 
ITAM domain of  DAP12 were mutated against phenylalanine (DAP12 Y92F Y103F-HA) was co-transfected 
with TREM2 (last lane). Cells were starved for 30 min in phosphate-free media and then incubated with 32P-
orthophosphate for 1 h. The TREM2/DAP12 system was then activated by incubation with 10 µg/ml anti-myc 
antibody. After further incubation of  1 h in presence or absence of  200 µM orthovanadate (OV), cells were 
lysed and an IP was performed with anti-HA antibodies to precipitate HA-tagged DAP12. Proteins were separ-
ated on a tris-tricine gel and transferred to a nitrocellulose membrane. Radiolabeled proteins were visualized by 
autoradiography (upper panel, 32P). After exposure, DAP12-HA was detected on the same membrane by west-
ern immunoblotting with anti-HA antibody (lower panel, WB)
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the  presented  TREM2  processing  nothing  is  known  about  the  function  of  γ-secretase  in 
microglia.
To test the involvement of  γ-secretase in the phagocytosis of  fAβ by microglia cells, BV-2 cells 
stably expressing PS1 WT, PS1 DN or PS1 L166P were generated. These stable BV-2 clones were 
incubated with fluorescently labeled fAβ. After 18 h the phagocytosis was measured by micro-
titer plate based photospectrometry (fig. 25; see 2.3.15).
The expression of  the DN variant of  presenilin and the mutated variant L166P reduces the pha-
gocytosis of  fAβ significantly, showing that γ-secretase might be involved in phagocytosis of  Aβ 
in microglia cells.
Figure 25: γ-secretase is involved in the phagocytosis of  fibrillar Aβ.
BV-2 cells  stably expressing PS1 WT, DN or the mutant  variant  L166P where incubated with fluorescent 
labeled fibrillar Aβ for 18 h. After quenching excessive Aβ outside the cells, the fluorescence was measured in a 
fluorescence spectrometer. For detailed protocol see 2.3.15.
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 4 DISCUSSION
Phagocytosis of  cell debris, apoptotic cells, lipids, aggregated proteins or other waste material is 
one of  the main function of  microglia. Depending on the ingested material  they exert either 
pro- or an anti-inflammatory responses.
In the AD brain, microglia with a proinflammatory phenotype are found in proximity to Aβ 
plaques, suggesting Aβ phagocytosis (Perlmutter et al., 1990; Frautschy et al., 1998; Bolmont et 
al., 2008; Meyer-Luehmann et al., 2008). There are several in vitro studies showing the ability of  
microglia to phagocytose Aβ (Koenigsknecht & Landreth 2004; Mandrekar et al., 2009; Hjorth et 
al., 2010; Nagano et al.,  2010; Smith et al.,  2010).  In vivo uptake of  injected sAβ and fAβ by 
microglia has also been demonstrated  (Weldon et al., 1998; Takata et al., 2003). However, the 
ablation of  microglia don't result in significant decrease of  plaque growth or plaque development 
(Grathwohl et al., 2009), suggesting only a minor role of  microglia in plaque formation, mainten-
ance and clearance in vivo. Nevertheless, activation of  microglia and phagocytosis of  Aβ play an 
important  role  in  AD  as  demonstrated  by  studies  with  APP  transgenic  mice  lacking  the 
chemokine receptor CCR2. These mice show less microglia activation and Aβ phagocytosis, res-
ulting in increased AD progression and mortality (El Khoury et al., 2007).
Since Aβ accumulates in the brain of  AD patients, there is obviously an insufficient clearance of  
Aβ by microglia under physiological conditions, because one function of  microglia is the removal 
of  waste material from the CNS (see 1.3). However, whether microglial phagocytosis in AD brain 
is defective is unclear..
Since  γ-secretase has been linked to endocytosis processes previously  (Tamboli et al., 2008), it 
might also be implicated in the regulation of  phagocytosis in microglia.
Indeed, a very recent paper demonstrated a role of  the γ-secretase component PS in the phago-
cytosis of  Aβ. The treatment of  the microglial cell line N9 with γ-secretase inhibitors decreased 
the  phagocytosis  of  fAβ42.  The  phagocytosis  was  further  diminished  after  shRNA mediated 
knock down of  PS1 as well as in primary microglia of  PS2 knock out mice (Farfara et al., 2010). 
However, the molecular mechanisms underlying γ-secretase dependent regulation of  phagocyt-
osis is unknown.
In this work it it shown that the triggering receptor TREM2 which is expressed on several myel-
oid cells including microglia is cleaved by γ-secretase. Prior to the γ-secretase cleavage the ectodo-
main of  TREM2 is shed by a metalloprotease. The inhibition of  TREM2 processing alters the 
interaction with its co-receptor DAP12. Moreover, blocking of  the γ-secretase cleavage impairs 
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phosphorylation of  the ITAM motif  of  DAP12, which is necessary for downstream signaling of  
TREM2 and DAP12. 
Thus, cleavage of  TREM2 and impaired DAP12 signaling could be a link between PS deficiency 
and phagocytosis defects, as observed in PS deficient microglia cells (Farfara et al., 2010)(see also 
chapter 3.4.1).
In accordance with this hypothesis TREM2/DAP12-dependent signaling was previously shown 
to regulate  levels  of  proinflammatory  cytokines  after  activation  of  TLRs  (Hamerman et  al., 
2006). and linked to phagocytosis processes (Takahashi et al., 2005; Takahashi et al., 2007; Hsieh 
et al., 2009; N'Diaye et al., 2009). 
 4.1 Proteolytic processing of  TREM2
Regulated intramembrane proteolysis (RIP) is a sequential mechanism liberating proteins from 
the lipid-bilayer. In the first step, cleavage by a sheddase, results in release of  the ectodomain and 
the generation of  a membrane-bound fragment of  the protein. This part which consists of  a 
small lumenal stub, a tm-domain and a cytoplasmic domain is then cleaved by a protease within 
the tm-domain, releasing both the lumenal part and the C-terminal domain from the membrane. 
 4.1.1 Shedding of  the TREM2 ectodomain
Detection of  soluble TREM2 ectodomain in cell culture supernatants (see chapter 3.2.4) estab-
lished the shedding of  TREM2. Well established sheddases are the members of  the ADAM and 
the MMP families. Additionally, aspartate proteases like BACE-1 and -2 are also known to act as 
sheddases.  While the members of  the APP family (APP and APLPs) are the only known sub-
strate  for  BACE-2,  BACE-1 has several  substrates.  One of  the  first  identified substrates  of  
BACE-1 was the sialyltransferase ST6Gal I  (Kitazume et al., 2003). However, the most studied 
substrates are APP (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; 
Lin et  al.,  2000) and neuregulin which is involved in myelination processes  (Hu et al.,  2006; 
Willem et al., 2006; Hu et al., 2008). By the use of  different protease modulators this work indic-
ates that a protease of  the ADAM or MMP family can shed TREM2 ectodomain (fig.  20,  21). 
However, these data don't rule out that other proteases, which might not be affected by the used 
modulators, contribute to TREM2 shedding. It might also be possible that TREM2 ectodomain 
shedding occurs by different proteases dependent on the intracellular localization and transport 
of  both the protease and TREM2. This is known for APP, which ectodomain can either be shed 
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by ADAMs (Buxbaum et al., 1998; Koike et al., 1999; Lammich et al., 1999), BACE-1 or -2 (Hus-
sain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999; Lin et al., 2000) or MMPs 
(Higashi & Miyazaki 2003; Ahmad et al., 2006; Yin et al., 2006; Talamagas et al., 2007). To further 
identity the TREM2 sheddase, surface stainings as shown in fig.  21 after treatment with more 
specific inhibitors are required. Alternatively, the generation of  the TREM2 ECD could be meas-
ured after siRNA mediated knockdown of  specific proteases or in knock out cells.
APP has been shown to be constitutively shed by ADAMs (Slack et al., 2001). Recently ADAM-
10 has been established as the constitutively active α-secretase of  APP in primary neurons (Kuhn 
et al., 2010). The low staining of  myc-TREM2-GFP on the cell-surface of  untreated COS7 cells 
(see fig. 21 G-L) suggests that TREM2 might be shed constitutively as well. However, the shed-
ding could further be induced by treatment with the phorbol ester PDBu (see fig. 21 D-F). The 
effect of  PDBu is most likely based on the property of  phorbol ester to activate PKC (Blumberg 
1988) and the resulting stimulation of  ADAMs as shown for APP (Jolly-Tornetta & Wolf  2000; 
Skovronsky et al., 2000). The way in which PKC stimulates ADAMs is still not fully understood. 
Three main pathways are suggested. PKC can either phosphorylate the ADAMs directly, as has 
been shown by Jacobsen and colleagues (Jacobsen et al., 2010) or PKC can affect the transloca-
tion of  ADAMs  (Yang et al., 2007; Kohutek et al., 2009). Furthermore, PKC increases vesicle 
budding from the Golgi (Xu et al., 1995), thereby increasing the transport of  both substrate and 
proteases to cell compartments where cleavage can occur. This would explain how the effect of  
the PKC activator TPPB which increases ADAM activity can be blocked by the transport inhib-
itor Brefeldin A (Yang et al., 2007).
In addition to phorbol ester, ADAM mediated shedding of  APP was shown to be inducible by 
insulin growth factor-1 in a PKC dependent manner (Jacobsen et al., 2010).
The reduced ECD levels in HEK293 PS1 WT cells after ligation of  TREM2 by an anti-myc 
antibody  (see  fig.  17)  indicate  that  ligand binding to  TREM2 might  protect  the full  length 
receptor  from  ectodomain  shedding.  A  possible  explanation  might  be  that  ligand  binding 
induces dimerization of  TREM2, resulting in a  sterical  blockade of  an  interaction with  the 
respective sheddase. Such an effect was shown for binding of  growth hormones to the growth 
hormone receptor (Zhang et al., 2001). Alternatively, ligand engagement could directly alter the 
three  dimensional  structure  of  TREM2 thereby masking  the sheddase cleavage site.  This  is 
known for Notch but in contrast to the findings regarding TREM2, binding of  the Notch ligand 
is necessary to induce shedding of  Notch ECD (Mumm & Kopan 2000; Mumm et al., 2000). 
Before ligand binding, Notch is locked in a protease-resistant state. Exposure to the ligand res-
ults in a conformational shift,  unfolding the sheddase cleavage site  (Bozkulak & Weinmaster 
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2009).  The  induction  of  shedding  by ligand  binding  has  also  been  shown for  the  vascular 
endothelial growth factor (VEGF) receptor-1 which is rendered susceptible to shedding sub-
sequently to phosphorylation induced by binding of  VEGF-A (Rahimi et al., 2009). 
The  reduced  TREM2 FL after  activation of  TREM2 by antibody ligation might  be due to 
enhanced endocytosis of  the full length receptor after ligand binding (see fig. 17). Such a down-
regulation of  receptor signaling by endocytosis and degradation of  receptor-ligand complex is a 
well established process, known for multiple receptors e.g. insulin receptor, EGF receptor (Sor-
kin & Duex 2010) and the IL-2 receptor (Legrue et al., 1991). TREM2 FL levels are reduced in 
HEK293 PS1 DN cells compared to HEK293 PS1 WT. However, activation of  TREM2 by anti-
body ligation don't affect the TREM2 FL levels in HEK293 PS1 DN (see fig. 17 C), suggesting 
less efficient endocytosis of  TREM2 after ligand binding in these cells. One explanation for this 
observation might be the general impairment of  endocytosis upon γ-secretase inhibition (Tam-
boli et al., 2008). Further endocytosis assays and antibody uptake assays are necessary to assess 
the contribution of  endocytosis in receptor down-regulation. 
The ectodomain shedding of  TREM2 would be consistent with the presence of  soluble variants 
of  TREM1 (sTREM1) in blood serum and plasma of  septic shock patients (Gibot et al., 2004; 
Mahdy et al., 2006) and TREM2 (sTREM2) detected in human CSF as described in the literature 
(Piccio et al.,  2008). The origin of  sTREM is discussed controversially, in particular  because 
sTREMs are found with or without association to DAP12. It was postulated that either a splice 
variant results in sTREM (Gingras et al., 2002) or that it is shed from membrane bound TREMs. 
sTREM1 levels decrease upon treatment of  human monocytes with metalloprotease inhibitors 
which might  suggest  shedding  (Gomez-Pina  et  al.,  2007).  This  is  further  supported  by the 
molecular weight of  ~27 kDa determined for sTREM1 (Gibot et al., 2004). Nothing is known 
about the size of  the sTREM2 fragment. However, based on the amino acid sequence, the ecto-
domain of  TREM1 should be larger then the ectodomain of  TREM2 (Bouchon et al., 2000). 
This led to the assumption that the ~15 kDa soluble fragment detected in this study (see fig. 17) 
represents a sTREM2 variant as described by Piccio and colleagues. Although, little is known 
about the function of  the sTREMs they are suggested to negatively regulate TREM signaling by 
neutralizing TREM ligands (Bouchon et al., 2001a; Piccio et al., 2007; Piccio et al., 2008)
TREM2/DAP12 complexes could interact in cis with plexin-A1 as well as in trans with the plexin-
A1 ligand semaphorin 6D, forming a higher order multimeric complex and regulating cellular 
adhesion and motility  (Takegahara  et  al.,  2006).  Co-IPs with  TREM2 and different deletion 
mutants of  plexin-A1 identified the interaction site in the extracellular located TIG domain of  
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plexin-A1. This, and the interaction of  TREM2 with semaphorin 6D in trans, suggest an interac-
tion via the TREM2 ectodomain. Thus, a shedding of  the TREM2 ectodomain might negatively 
regulate the interaction with plexin-A1, thereby modulating cellular motility and axon guidance. 
This might contribute to the migration defects which our lab recently observed in PS1 deficient 
BV-2 cells (data of  Sonia Tosheva, not shown) and which were confirmed by a very recent 
paper, demonstrating migration deficits in N9 cell after treatment with γ-secretase inhibitors as 
well as in primary microglia of  PS2 -/- mice (Farfara et al., 2010). According to this, it would be 
interesting to  study migration of  microglia  cells  in  response to  overexpression of  different 
TREM2 variants or after treatment with shedding modulators. Furthermore, TREM2 -/- (Seno et 
al., 2009) mice could be analyzed for axonal alterations. If  they exhibit an axonal phenotype, the 
contribution of  plexin A1 and semaphorin 6D, can be further analyzed in more detail.
It  is  well  established  that  shed  ectodomains  serve  as  ligands  for  other  receptors.  sAPP for 
example can bind to DR-6 inducing axonal pruning and neuronal death (Nikolaev et al., 2009). 
Additionally, the shed ectodomain of  E-cadherin which binds to ErbB receptors promotes their 
activation  (Najy et al.,  2008).  Thus, the TREM2 ectodomain might also serve as a ligand for 
another receptor. Further experiments are required to analyze the stability of  the ectodomain 
and to find and identify putative binding partners. 
 4.1.2 Cleavage of  TREM2 CTF by γ-secretase
Ectodomain shedding of  type I membrane proteins is required for subsequent cleavage of  the 
membrane-tethered CTF by γ-secretase.  Besides γ-secretase, there are four different classes of  
intramembrane proteases which can catalyze the cleavage reaction within the membrane: The sig-
nal peptide peptidases (SPP) (Grigorenko et al., 2002; Ponting et al., 2002; Weihofen et al., 2002), 
the signal peptide peptidase like proteins (SPPLs) which cleave TNFα (Fluhrer et al., 2006; Fried-
mann et al., 2006), the site-2 proteases (S2P)  (Rawson et al., 1997) known for the cleavage of  
sterol regulatory element binding proteins (SREBPs) and the rhomboid serine proteases which 
cleave transmembrane ligand substrates e. g. the EGF ligand Spitz in  Drosophila  (Urban et al., 
2001; Freeman 2004). However, all these protein classes have specific requirements for their sub-
strate CTFs. Only γ-secretase cleaves CTFs of  type I transmembrane proteins. 
Pharmacological inhibition of  the γ-secretase complex with the specific inhibitor DAPT (Dovey 
et al., 2001) and subsequent accumulation of  a TREM2 CTF fragment (see chapter. 3.1.2) reveal 
that TREM2 CTF is a γ-secretase substrate. This is supported by demonstration of  TREM2 CTF 
accumulation after co-expression with PS1 DN (see chapter. 3.1.2). Both methods are well estab-
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lished to prove γ-secretase mediated cleavage of  the main γ-secretase substrates APP (Steiner et 
al., 1999; Kim et al., 2001) and Notch (Berezovska et al., 2000; Jack et al., 2001). PS1 DN is an 
artificial PS mutant of  a critical aspartyl residue in the active site which doesn't occur in AD 
patients. However, there are mutations of  PS1 linked to EOAD which cause partial loss of  γ-
secretase function according to cleavage of  APP and Notch (see 1.1.2.2). The accumulation of  
TREM2 CTF in the tested PS FAD variants L166P and ∆Ex9 (see chapter. 3.1.2) indicates that a 
partial loss of  γ-secretase function is sufficient to impair TREM2 processing and suggests contri-
bution of  TREM2 cleavage impairment in AD pathology of  patients with PS dependent EOAD. 
According to the age-of-onset of  AD, L166P and ∆Ex9 are severe mutations. Thus, it would be 
interesting  to  check  whether  weaker  PS  mutations  with  a  later  age-of-onset  are  also  inhibit 
TREM2 processing.
Although γ-secretase is located in the Golgi,  TGN, secretory vesicles,  plasma membrane and 
lysosomes/endosomes, substantial γ-secretase activity is located on the plasma membrane and/or 
endosomes (Kaether et al., 2006a; Kaether et al., 2006b), implicating that cleavage of  substrates 
occurs at the cell surface. Indeed, TREM2 CTF was found in immunofluorescence experiments 
to accumulate at the cell surface upon γ-secretase inhibition (see chapter 3.2.1). Moreover, expres-
sion of  a truncated TREM2 construct (TREM2∆ECD) which lacks the ectodomain of  TREM2 
and thereby resembles an immediate γ-secretase substrate accumulates at the cell surface as well 
(see chapter 3.2.1). The surface localization of  TREM2 CTF was approved and quantified by sur-
face biotinylation studies (see chapter 3.2.1). The observed plasma membrane localization is con-
sistent with accumulation of  APP CTFs at the cell  surface that follows γ-secretase inhibition 
(Kim et al., 2001). The same was shown for Notch, inhibition of  γ-secretase either by pharmaco-
logical inhibitors or by point mutations in presenilin has been shown to end up in the accumula-
tion of  NEXT (Notch extracellular truncation) (Mumm et al., 2000).
Besides APP and Notch, the γ-secretase complex cleaves several type I transmembrane proteins. 
All of  them are expressed on various cell types, but a microglia-specific substrate has not yet 
been demonstrated. Thus, TREM2 is the first identified microglia-specific γ-secretase substrate. 
γ-Secretase cleaves substrate CTFs within the tm-domain, resulting in liberation of  extracellular 
and lumenal parts from cellular membranes. While the physiological functions of  extracellular 
peptides are largely unknown, certain ICDs (see 1.1.5.3) translocate to the nucleus and serve as 
transcriptional co-factor for gene regulation. This has been demonstrated for Notch, which ICD 
regulate the transcription of  developmental genes (Mumm & Kopan 2000). To shut off  the tran-
scriptional regulation, NICD can be degraded via the ubiquitin-proteasome pathway  (Gupta-
Rossi et al., 2001; Oberg et al., 2001). AICD in contrast is very unstable and degraded rapidly by 
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the proteasome or IDE (Edbauer et al., 2002a; Buoso et al., 2010). However, some studies sug-
gest a gene regulatory function of  AICD most likely after stabilization by adapter proteins like 
Fe65 (Kimberly et al., 2001; Buoso et al., 2010). Notably, there are several other ICDs (e. g. ICDs 
of  syndecan-2, nectin-1α and p75) which are rapidly degraded after their release by γ-secretase 
(Kopan & Ilagan 2004).
In all experiments there was no ICD of  TREM2 (TICD) detectable, suggesting a fast degrada-
tion by either the ubiquitin-proteasome pathway or other proteases for example in the lysosome. 
To test this, TICD detection in cells treated with either proteasome inhibitors like MG132, or 
lysosomal inhibitors like NH4Cl is required.
Overexpression of  recombinant TICD-like fragment in HeLa cells doesn't reveal a nuclear local-
ization (fig. 16), indicating that a transcriptional activity of  TICD is unlikely. The staining pattern 
of  the TICD-like fragment rather indicated a vesicular localization. However, the identity of  
these vesicles is unclear. Since lysosomal degradation of  the Notch3 ICD (Jia et al., 2009) and 
the ErbB4 ICD (Zeng et al., 2009) has been already established, the observed vesicular staining 
might represent lysosomes. Future co-stainings of  the TICD-like fragment and different com-
partment markers could help to identify the observed vesicles.
Based on the above findings, presence of  TICD and contribution to nuclear signaling is unlikely, 
but could not be completely ruled out, because stabilization by an putative adapter protein was 
not tested. Such an stabilizing effect has been shown for Fe65 on the AICD. It might also be 
possible that an adaptor protein directly inhibit the TICD degrading enzymes.
As discussed for shedding, γ-secretase cleavage can also be induced by ligand binding. TREM2 
CTF levels are slightly elevated in HEK PS1 DN cells upon activation (fig.  15) but not in PS1 
WT cells. Thus, an effect of  ligand binding on γ-secretase cleavage of  TREM2 is unlikely, but 
the slight increase of  CTFs could be indirectly caused by increased shedding after ligand binding. 
However,  the  demonstration of  constitutive  shedding of  TREM2 (see  fig. 21 G-L) and the 
unchanged TREM2 ECD levels in HEK PS1 DN cells upon activation (see fig. 17) rather favor 
a model in which ligand binding stabilizes TREM2 FL. 
Taken together, TREM2 undergoes constitutive shedding by ADAMs or MMPs in absence of  a 
ligand, releasing a ~15 kDa ectodomain to the supernatant. The ectodomain release is stimulated 
by phorbol esters supporting the role of  ADAMs. The observed shedding could thereby provide 
an explanation for the occurrence of  sTREM2 in cerebrospinal fluid (Piccio et al., 2008). The 
remaining  CTF  is  subsequently  cleaved  by  γ-secretase  releasing  an  ICD  which  is  rapidly 
degraded by the proteasome or in lysosomal compartments. All these findings clearly indicate 
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that TREM2 undergoes RIP. However, presence of  a ligand seems to stabilize TREM2 FL at the 
cell surface and might induce endocytosis of  the TREM2-DAP12-ligand complex. 
 4.2 γ-secretase dependent interaction of  TREM2 and DAP12
 4.2.1 Inhibition of  γ-secretase cleavage alters interaction of  TREM2 with DAP12
Since TICD seems to be rapidly degraded, it is unlikely that the main function of  TREM2 RIP is 
the release of  a transcriptional active fragment. Furthermore, a function of  RIP in the down-reg-
ulation of  signaling is unlikely. Thus, the function of  TREM2 RIP remains unclear. One putative 
function of  RIP could be the degradation of  membrane localized TREM2 in absence of  a ligand 
(see fig. 26, right side). This would coincide with the hypothesis that γ-secretase has a general role 
in degradation of  membrane proteins (Kopan & Ilagan 2004).
Intracellularly, TREM2 is mainly localized in the Golgi complex and in cytoplasmic vesicles with 
constitutive shuttling to the plasma membrane (Sessa et al., 2004; Prada et al., 2006). Absence of  
a ligand or an interaction partner like plexin-A1 might therefore result in the accumulation of  the 
full length receptor inside the membrane. Under these conditions, RIP might be the mechanism 
to remove TREM2 FL from the membrane (see fig. 26, right side). This hypothesis is supported 
by  the  vesicular  staining  seen  in  TREM2  overexpressing  cells  without  DAPT  treatment 
(see fig. 11).  These  stainings were  achieved with an antibody against  the  C-terminal  myc-tag, 
which is part  of  the TICD liberated by γ-secretase from TREM2. Thus,  the staining pattern 
might represent vesicular structures, either containing myc-tagged TICD or uncleaved TREM2 
CTFs. This idea is supported by the finding that overexpression of  a TICD-like fragment results 
in a comparable staining pattern (see fig. 16).
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Presence and binding of  a ligand might protect TREM2 FL against ectodomain shedding. This is 
supported by decreased levels of  TECD in HEK293 PS1 WT cells upon TREM2 activation (see 
fig.  17). Since ectodomain shedding is an absolute prerequisite for subsequent γ-secretase cleav-
age, this processing step is also blocked. Hence, TREM2 FL is stabilized at the membrane and 
can engage with the co-receptor DAP12, stimulating downstream signaling via activation of  Syk 
(see fig.  26, left side). To down-regulate the signaling, the binding of  the ligand might further 
induce endocytosis of  the TREM2-DAP12-ligand complex as indicated by the reduced levels of  
TREM2 FL after activation  (see fig.  17). However, the results with increased TREM2 CTFs in 
HEK PS1 DN cells after activation (fig. 15), don't support this model.
Figure 26: Hypothetical scheme for the sequential processing of  TREM2.
In absence of  a ligand, ectodomain of  membrane-accumulated TREM2 FL (blue box) is first shed by a shed-
dase of  the ADAM or MMP family, leaving the TREM2 CTF inside the membrane. This small stub is then 
cleaved by γ-secretase into two small fragments which are immediately degraded. In presence of  a ligand the 
full-length receptor is  stabilized.  Ligand binding further induces dimerization with DAP12, favoring phos-
phorylation of  the ITAM domain by a Src-family kinase. Phosphorylated ITAM recruits Syk, which then activ-
ates the downstream signaling cascade. To down-regulate the signaling the TREM2-DAP12-ligand complex is 
taken up into the cells most likely through endocytosis. TECD, TREM2 extracellular domain; L, ligand; TICD, 
TREM2 intracellular domain.
DISCUSSION 93
Based on the model established above (fig. 26), inhibition of  γ-secretase should result in the accu-
mulation of  TREM2 CTF at the membrane. Indeed, this was shown in this work (fig.  9-13). 
Interaction between TREM2 and DAP12 is mediated by the charged lysine residue inside the tm-
region (see 1.5 and 1.6). Since the tm-domain is part of  the accumulating CTFs these fragments 
can engage with DAP12. Accordingly, the CTFs might be able to trap DAP12. Thus, the amount 
of  co-receptor available to engage with TREM2 FL, or other DAP12 associated receptors, such 
as signal regulatory protein-β1 (SIRPβ1) (Tomasello & Vivier 2005; Gaikwad et al., 2009) or com-
plement receptors  (Mocsai et al.,  2006) would be reduced. This in turn would prevent phos-
phorylation of  DAP12 and blocks activation of  the downstream located Syk. In consequence of  
this, downstream signaling of  TREM2/DAP12 or other DAP12 associated receptors would be 
impaired (see fig. 27). Since TREM2-DAP12 signaling regulates phagocytosis processes, impaired 
interaction of  functional TREM2 FL with DAP12 through γ-secretase inhibition would result in 
a phagocytosis defect. 
 4.2.2 Inhibition of  γ-secretase impairs DAP12 phosphorylation
The accumulation of  TREM2 at the plasma membrane (fig. 12 and 13) and the altered interaction 
of  TREM2 with DAP12 upon γ-secretase inhibition (fig. 22, 23), support the model established 
in  fig.  27.  Moreover,  the phosphorylation of  DAP12 was found to be  impaired.  Notably,  γ-
Figure 27: Hypothetical scheme of  impaired TREM2 processing upon γ-secretase inhibition.
After ectodomain shedding of  the full length TREM2 (blue box), TREM2 CTFs accumulate in the membrane, 
because subsequent  degradation of  the  CTFs is  blocked due to an inactive  γ-secretase.  Thus,  CTFs trap 
DAP12 thereby preventing interaction with the FL receptor, witch is stabilized by ligand binding. This results 
in an incomplete phosphorylation of  the ITAM domain, failed activation of  Syk and impaired downstream sig-
naling. TECD, TREM2 extracellular domain; L, ligand.
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secretase inhibition doesn't result in full blocking of  the DAP12 phosphorylation but in a mono-
phosphorylated ITAM domain (fig. 24).
It was previously shown that dependent on the interacting receptor, DAP12 mediated signaling 
could either be activatory or inhibitory. For example signaling via DAP12 and MDL-1 (myeloid 
DAP12-associated lectin 1) results in calcium mobilization and cellular activation (Bakker et al., 
1999).  In  contrast,  as  mentioned  in  the  introduction  (see  1.5.2),  activation  of  DAP12  and 
TREM2 results in inhibition of  TLR responses (Hamerman et al., 2006). To explain this paradox 
Turnbull  & Colonna established a  hypothesis in  which the  phosphorylation state  of  DAP12 
(monophosphorylated or full phosphorylated) directs the downstream signaling either to activat-
ory or inhibitory cell response (Turnbull & Colonna 2007). Based on this hypothesis, high avidity 
ligands are suggested to lead to a full phosphorylation of  the DAP12 ITAM domain, whereas the 
binding of  a low avidity ligand is suggested to activate SH2-domain-containing protein tyrosine 
phosphatase 1 (SHP1). Thereupon, SHP1 deactivates Src kinases in the signaling complex, pre-
venting full phosphorylation of  the DAP12 ITAM motif, thereby stabilizing DAP12 in a mono-
phosphorylated state. This in turn blocks binding and activation of  Syk and the downstream loc-
ated PLCγ (see fig.  28, left side).  PLCγ catalyzes the degradation of  phosphatidylinositol-4,5-
bisphosphate (PtdIns(4,5)P2) which is necessary to anchor two proteins involved in the TLR sig-
naling cascade, MyD88 (myeloid differentiation primary-response gene 88) and TIRAP (Toll/IL-
1-receptor-domain-containing  adapter  protein).  Thus,  inhibited  PLCγ  would  stabilize 
PtdIns(4,5)P2 in the membrane, allowing binding of  MyD88 and TIRAP (Kagan & Medzhitov 
2006). Finally,  this cascade could stabilize the TLR response (fig.  28, left side).  Moreover, the 
inactive Syk kinase might fail to activate phosphatidylinositol-3 kinase (PI3K) (Vieira et al., 2001; 
Huang et al., 2006). This inhibits inactivation of  AKT which in turn amplifies activation of  the 
mitogen  activated  protein  kinase  kinase  kinase  (MAPKKK;  fig.  29,  left  side  )  (Turnbull  & 
Colonna  2007;  Ivashkiv  2009).  Recently,  an additional  indirect  pathway was shown,  coupling 
DAP12 signaling via intergrins to the inhibition of  TLRs and to the increased expression of  the 
anti-inflammatory cytokine IL-10  (Wang et al., 2010). This pathway would also be impaired by 
reduced DAP12 phosphorylation, thereby facilitating TLR response resulting in higher levels of  
proinflammatory cytokines. 
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Inhibition of  γ-secretase reduces the phosphorylation state of  DAP12 (see chapter 3.3.3), which 
according to the hypothesis of  Turnbull & Colonna could evoke both activatory or inhibitory cell 
responses.  Thus,  RIP  might  enable  cells  to  switch  between  pro-  and  anti-inflammatory  cell 
response.
As already discussed, some RIP processes involved in receptor signaling base on the release of  an 
ICD as signal mediating fragment. Thus, RIP of  TREM2 demonstrated in this work, is the first 
RIP dependent signaling cascade in which not the ICD, but the CTF functions as signal mediat-
ing fragment.
Figure 28: Impaired DAP12 signaling stabilizes TLR response via PLCγ.
In the defective signaling pathway (left side) monophosphorylated DAP12 blocks binding and activation of  
Syk. Inactive PLCγ stabilizes PtdIns(4,5)P2 in the membrane. Recruitment of  TIRAP and MyD88 facilitate 
TLR response which results finally in proinflammatory cytokine production. In the intact signaling pathway 
(right  side)  Syk  is  activated  by  a  completely  phosphorylated  DAP12,  thereby  stimulating  degradation  of  
PtdIns(4,5)P2  by PLCγ. PtdIns(4,5)P2 functions as a docking site for TIRAP and it is required for recruitment 
of  MyD88 to the TLR complex. Thus, PtdIns(4,5)P2 degradation through activated PLCγ impairs TLR signal-
ing.  IP3,  inositol  triphosphate;  DAG, diacylglycerol.  Modified from “Activating and inhibitory functions of  
DAP12” (Turnbull & Colonna 2007).
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Notably,  c-Src  transcription  is  downregulated  in  response  to  reduced  ephrin  B2  signaling  in 
PS dko MEF cells and upon pharmacological γ-secretase inhibition  (Waschbusch et al., 2009). 
Since it is not clear which kinase of  the Src family is responsible for the DAP12 phosphorylation, 
the  reduced c-Src levels  upon γ-secretase  inhibition might  contribute  to the  impaired ITAM 
phosphorylation. It was further shown, that the ephrin B2 intracellular domain which is released 
after γ-secretase cleavage can directly bind Src. This in turn impairs the interaction with the inhib-
itory kinase Csk, allowing autophosphorylation of  Src, thereby facilitating Src activity (Georgako-
poulos et al., 2006).
Figure 29: Impaired DAP12 signaling stabilizes TLR response via PI3K.
In the defective signaling cascade (left side) unbound Syk fail to activate PI3K, thereby stabilizing AKT activity. 
AKT activates  MAPKKK a  kinase  in  the  downstream signaling  of  TLR,  ending  up  in  proinflammatory 
cytokine production. In the intact signaling cascade (right side) bound and activated Syk stimulates PI3K which 
in turn facilitates phosphorylation of  AKT. Phosphorylated and thus inactivated AKT fails to phosphorylate 
MAPKKK. This in the end impairs production of  proinflammatory cytokines. Modified from “Activating and 
inhibitory functions of  DAP12” (Turnbull & Colonna 2007)
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 4.3 Potential effects of  impaired TREM2/DAP12 signaling on 
phagocytosis and degradation of  Aβ
Many studies have linked TREM2 to phagocytosis but the potential mechanism underlying this 
effect is unclear. Regulation of  PLCγ and PI3K activity by DAP12 signaling (Jiang et al., 2002; 
Mao et al., 2006; Peng et al., 2010) might be involved. Impaired TREM2 signaling  might thereby 
result in changed turnover of  phosphatidylinositols (PtdIns) in the membrane.
PtdIns(4,5)P2 is an important signaling lipid (~1-2 % of  the whole content) of  the inner leaflet 
of  the membrane (Tran et al., 1993; Raucher et al., 2000) which is well known to be involved in 
actin filament reorganization and extension (Takenawa & Itoh 2001). It was also found to play an 
important role during phagocytosis. While PtdIns(4,5)P2 accumulates in the forming phagosome 
at the basement, it has been shown that its deprivation, accompanied with actin disassembling is 
essential  for  phagosome sealing  (Botelho et  al.,  2000).  Impaired PtdIns(4,5)P2 metabolism or 
overexpression of  the PtdIns(4,5)P2 forming enzyme  phosphatidylinositol  phosphate kinase I 
prevents  actin  disassembly,  necessary  for  the  completion of  phagocytosis  (Scott  et  al.,  2005; 
Cheeseman et  al.,  2006).  Most  likely  the  observed  deprivation of  PtdIns(4,5)P2 results  from 
hydrolysis by PLCγ which is recruited to the phagocytic cup through the SH2 domain. Hydrolysis 
of  PtdIns(4,5)P2 results in the release of  IP3 and DAG. IP3  as a Ca2+-channel regulator, also plays 
a crucial role in phagocytosis because the occurrence of  Ca2+-transients during phagocytosis is 
well established (Nunes & Demaurex 2010). The role of  DAG is not that clear, but it can induce 
negative curvatures of  lipid membranes due to its small polar head group. Thus, it is suggested to 
be involved in membrane bulging and fission (Carrasco & Merida 2007). PtdIns(4,5)P2 serves fur-
ther as source for phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) another lipid found 
to be accumulated in the phagocytic cup. It is also established to be responsible for recruitment 
of  myosin X, a motor protein important for pseudopod extension and closure of  the phagosome 
(Cox et al., 2002). Generation of  PtdIns(3,4,5)P3 is catalyzed by PI3K which has to be activated 
by binding of  active Syk to the p85 regulatory subunit. It has been shown that inhibitors of  PI3K 
like Wortmannin affected the phagocytosis of  large particles (< 3 µm in diameter), while smaller 
particles remain unaffected (Yeung & Grinstein 2007).
As discussed above, both PLCγ and PI3K are important for the metabolism of  PtdIns during 
formation  and  closure  of  phagosomes.  Decreased  γ-secretase  cleavage  and  impaired 
DAP12/TREM2 signaling might therefore alter the activity of  PLCγ and PI3K (see fig. 28) and 
the lipid composition in and around the phagosome. This would be a putative mechanism by 
which inhibited TREM2 processing can account for the blocked phagocytosis of  fAβ in BV-2 
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cells stably expressing PS1 FAD variants (see fig. 25) or for the phagocytosis defect demonstrated 
primary microglia of  PS deficient mice and in the microglia cell line N9 after downregulation of  
PS1 (Farfara et al., 2010).
TREM2 mediated phagocytosis is associated with decreased levels of  proinflammatory cytokines 
(Takahashi et al., 2005; Takahashi et al., 2007). Since PLCγ and PI3K regulate TLR signaling by 
the pathways illustrated in fig. 28 and 29, this would support the involvement of  these two pro-
teins in phagocytosis.
In the future, it would be interesting to measure the transition of  PtdIns(4,5)P2 with the help of  
the PH domain of  PLCδ (Raucher et al., 2000) in life cell imaging experiments upon γ-secretase 
inhibition. Moreover, measurements of  cytokine profiles could help to assess the contribution of  
γ-secretase  inhibition  to  the  regulation  of  pro-inflammatory  cytokines.  It  would  be  further 
important to analyze the triggering factor of  TREM2 signaling. Two different variants could be 
suggested which induce an ITAM mediated inflammatory cascade (see fig. 30). TREM2 might be 
activated either directly through Aβ or might be cross activated through an Aβ binding scavenger 
receptor. TREM2 has been found to be expressed in microglia surrounding Aβ plaques (Frank et 
al., 2008; Melchior et al., 2010). Binding studies of  TREM2 with different variants of  Aβ are 
necessary to check whether Aβ can serve as TREM2 ligand.  In vivo  phosphorylation assays can 
then be used to monitor the DAP12 phosphorylation state upon Aβ treatment. 
It has been reported that the uptake of  fAβ in vitro by BV-2 cells was attenuated under proinflam-
matory conditions  (Koenigsknecht-Talboo & Landreth 2005).  The authors  reported that fAβ 
activated BV-2 cells which then responded by generating a proinflammatory environment. The 
inflammatory mediated suppression of  fAβ uptake was dependent on NFκB activation, linking 
Aβ uptake to TLR response. Since ITAM signaling has been linked via the CARD9 directly to 
NFκB activation (Ivashkiv 2009), the suppression might be regulated by DAP12 or other ITAM 
containing co-receptors like FcRγ. Interestingly, the phagocytosis upon antibody mediated activa-
tion of  FcR is unaffected by the proinflammatory milieu. Thus, FcRγ the ITAM-containing co-
receptor  of  FcRs  might  not  be  involved  in  the  NFκB  activation.  The  levels  of  cytokines, 
chemokines and other proinflammatory molecules are elevated in brains of  AD patients as well 
as in animal disease models (Akiyama et al., 2000). This might explain why Aβ removal from the 
brain is observed after passive immunization with anti-Aβ antibodies (Bard et al., 2000; Bacskai et 
al., 2002; Wilcock et al., 2003) as well as active immunization with Aβ (Schenk et al., 1999), while 
the removal of  Aβ without vaccination is inefficient. Hickman and colleagues reported that the 
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levels of  Aβ degrading enzymes like IDE and NEP are reduced in primary microglia from APP-
PS1 transgenic mice in an age-dependent manner. This reduction is accompanied by inreased 
levels of  proinflammatory cytokines and a reduction of  Aβ scavenger receptors (Hickman et al., 
2008).
Taken together, the observed impaired γ-secretase cleavage of  TREM2 leads to accumulation of  
TREM2 CTFs in the plasma membrane, trapping DAP12. This in turn might block the interac-
tion with DAP12 associated receptors like TREM2 FL or  SIRPβ1 involved in  phagocytosis. 
Moreover,  the  DAP12  phosphorylation  state  is  impaired  due  to  altered  interaction  with 
TREM2 FL  preventing  activation  of  Syk.  Thus,  activation  of  PLCγ  and  PI3K  might  be 
impaired,  resulting in  a  facilitated  TLR response and a  stabilization of  PtdIns(4,5)P2 in  the 
microglia  membrane.  This  in  combination  with  the  elevated  levels  of  pro-inflammatory 
cytokines might then finally result in attenuated fAβ uptake and impaired degradation of  sAβ by 
degrading proteases (fig. 30).
This proposed cascade could thereby provide a mechanism by which γ-secretase inhibition can 
be linked to defective phagocytosis of  microglia, observed in PS deficient primary microglia 
(Farfara et al., 2010). This could further underlie the inefficient clearance of  Aβ in brains of  PS-
linked AD patients.
Figure 30: Hypothetical link between impaired TREM2 cleavage and attenuated Aβ phagocytosis and 
degeneration.
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 5 OUTLOOK
So far the inefficient phagocytosis and clearance of  Aβ by microglia in AD brains is not under-
stood. However, the impaired TREM2 processing demonstrated in this work, could provide an 
possible explanation.  Future experiments  in transgenic mice would be important to test patho-
physiological relevance.
TREM2 deficient mice (Colonna et al., 2007) could be crossed with an AD model like APP trans-
genic mice which produce increased levels of  Aβ. These mice could be then compared to control 
mice concerning the age of  plaque appearance.
The present findings indicate an involvement of  γ-secretase in TREM2 mediated migration and 
phagocytosis of  microglia. Thus, microglia behavior could be monitored in these mice by in vivo 
microscopy.
Alternatively, it would be feasible to inject different variants of  Aβ into the brains of  TREM2 
deficient mice and to analyze the time-dependent Aβ clearance compared to control mice. The 
different  variants  of  Aβ would  further  allow to  test  whether  TREM2 deficiency  affects  the 
uptake of  both sAβ and fAβ. However, the suggested  in vivo experiments would only allow to 
monitor the phagocytosis of  Aβ in respect to TREM2 deficiency and not to an impaired TREM2 
processing.  For  this  it  could  be  helpful  to  analyze  mice  with  a  conditional  PS  knockout  in 
microglia. In these mice the TREM2 processing could be proven by a C-terminal TREM2 anti-
body. Injection of  Aβ in these mice would further allow to analyze phagocytosis with respect to 
accumulation of  TREM2 CTFs. Finally, a transgenic mouse could be generated that overexpress 
the TREM2 CTF construct, used in this study, in microglia.
The cleavage of  APP CTFs by γ-secretase is a very important step in the development of  AD 
pathology. Modulation of  γ-secretase activity by artificial γ-secretase inhibitors is therefore a fre-
quently proposed therapeutic strategy against AD. However, based on the presented results, γ-
sceretase  might  also  regulate  microglia  activity  via  TREM2  processing.  An  inhibition  of  γ-
secretase could have therefore also detrimental effects for the progress of  AD. For this reason, it 
would be necessary to develop γ-secretase modulators which impair γ-sceretase cleavage of  APP 
CTFs, but don't affect the processing of  TREM2. Furthermore, it would be possible to develop 
specific inhibitors for the TREM2 sheddase. Inhibition of  the TREM2 sheddase stabilizes the 
TREM2 FL receptor and would thereby stimulate the TREM2/DAP12 signaling pathway and 
promote the uptake of  Aβ. 
Although the known clinical methods to diagnose AD in later stages are very efficient,  these 
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methods fail  to identify  risk patients.  For this purpose  biomarkers  are of  very high interest. 
sTREM2 has been previously detected in human blood and CSF (Gibot et al., 2004; Mahdy et 
al.,  2006;  Piccio et al.,  2008).  Since the demonstrated TECD seems to be similar with these 
sTREM2 variants, it  should  be  feasible  to  detect  TECD in  CSF of  AD patients.  A strong 
increase of  TECD in CSF would indicate an accumulation of  TREM2 CTFs which could result 
in impaired Aβ clearance by microglia and might indicate a higher risk to develop AD. The 
TREM2 Aβ-like fragment has not yet been detected in human CSF or blood. Thus, detection 
methods for this particular  fragment could be developed. Decreased levels  of  this  fragment 
would  then  directly  indicate  impaired  γ-secretase  activity.  Accordingly,  cleavage  products  of  
TREM2 like TECD and the Aβ-like peptide might be used as biomarkers.
ABSTRACT 102
 6 ABSTRACT
Alzheimer's  disease  (AD)  is  a  progressive  neurodegenerative  disorder,  affecting  millions  of  
people worldwide. AD is histopathologically characterized by the appearance of  neurofibrillary 
tangles, which are intraneuronal accumulations of  hyperphosphorylated tau protein, and extracel-
lular β-amyloid plaques. β-Amyloid plaques arise from progressive accumulation of  Aβ, a small 
hydrophobic peptide, in the brain. Aβ derives from sequential proteolytic processing of  the amyl-
oid precursor protein (APP). The final processing step in the generation of  Aβ is catalyzed by the 
γ-secretase  complex,  consisting  of  presenilin-1  (PS1),  the  active  subunit,  nicastrin,  Aph-1 
(anterior pharynx defective-1) and PEN-2 (presenilin enhancer element-2). Besides APP, the γ-
secretase has several other substrates and is also involved in the endocytosis of  membrane bound 
lipoprotein receptors. 
In addition to neurofibrillary tangles and amyloid plaques, activation of  microglia and inflammat-
ory  processes  are  also  fundamental  characteristics  in  the  brain  of  AD  patients.  Activated 
microglia  appear  to  play  a  dual  role  in  AD.  On  one  hand  they  produce  pro-inflammatory 
cytokines, reactive oxygen species and nitric oxide, augmenting inflammatory processes and oxid-
ative stress which might promote neuronal damage. On the other hand microglia can phagocyt-
ose Aβ, thereby contributing to its clearance from the brain. However, the accumulation of  Aβ in 
AD brains indicates an insufficient clearance of  Aβ in AD pathogenesis which is not yet under-
stood. Since γ-secretase was previously linked to endocytosis, it might also be implicated in pha-
gocytic processes by microglia and clearance of  Aβ.
Here it is shown by biochemical experiments in cell culture models, that the triggering receptor 
expressed on myeloid cells-2 (TREM2) represents a novel substrate for γ-secretase in microglia. 
Pharmacological inhibition of  γ-secretase resulted in accumulation of  a TREM2 C-terminal frag-
ment. This fragment also accumulated upon expression of  a dominant negative variant of  PS1. 
Immunofluorescence  and  biotinylation  experiments  further  indicated  that  the  processing  of  
TREM2 occurs at the plasma membrane. In addition, cell biological experiments demonstrated 
shedding of  the TREM2 ectodomain. Thus, TREM2 follows the canonical proteolytic processing 
pathway of  γ-secretase substrates which consists of  an initial cleavage within the ectodomain fol-
lowed by intramembranous cleavage of  the resulting membrane-tethered CTF by γ-secretase. The 
usage of  selective protease inhibitors also indicated the involvement of  a metalloprotease, likely 
of  the ADAM family, in TREM2 ectodomain shedding. TREM2 dependent signaling required the 
interaction with its co-receptor DAP12. Interestingly, co-immunoprecipitations revealed impaired 
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interaction of  TREM2 and DAP12 upon γ-secretase inhibition Moreover, the impaired interac-
tion  resulted  in  decreased  phosphorylation  of  DAP12.  Expression  of  different  PS1  FAD 
mutants, led to decreased phagocytosis of  Aβ. Thus, a partial loss of  γ-secretase activity might 
decrease the capacity of  microglia to clear Aβ.
Taken together, these results indicate a critical function of  γ-secretase in microglia and might help 
to understand molecular mechanisms underlying impaired Aβ clearance in the pathogenesis of  
AD.
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